Clinical Analytics Market - Global Forecast to 2030
商品番号 : SMB-90478
| 出版社 | MarketsandMarkets |
| 出版年月 | 2025年10月 |
| ページ数 | 495 |
| 図表数 | 494 |
| 価格タイプ | シングルユーザライセンス |
| 価格 | USD 4,950 |
| 種別 | 英文調査報告書 |
臨床分析市場 – オファリング（生データ、プラットフォーム）、ソース（EHR、試験、請求、RWE）、ユースケース（CDSS、RPM、PHM、R&D、医薬品安全性監視、精密医療、規制）、エンドユーザー（病院、支払者、製薬会社、医療技術）、地域別 – 2030年までの世界予測
臨床分析市場は2025年に330億9000万米ドルと評価され、2030年には813億2000万米ドルに達し、予測期間中に19.7%のCAGRを記録すると予測されています。市場の成長は、EHR、コネクテッド医療機器、遠隔モニタリングソリューションの広範な導入に伴う臨床データの爆発的な増加に牽引されており、高度な分析機能に対する切迫したニーズを生み出しています。AI、機械学習（ML）、高性能コンピューティングの進歩により、より高速で正確なデータ処理が可能になり、複雑なデータセットから実用的な洞察を引き出すことができます。医療機関が臨床試験、治療計画、価値に基づくケアモデルをサポートするために分析を活用するケースが増えているため、リアルワールドエビデンス（RWE）に対する規制の開放性が高まっていることで、導入がさらに加速しています。さらに、個別化医療や精密医療への移行により、診断、治療選択、および結果を最適化するための患者固有の分析に対する需要が高まっています。リアルタイムの臨床意思決定の必要性が高まるにつれ、患者の安全性の向上、エラーの削減、ケア提供の全体的な効率性の向上のための重要なツールとしての臨床分析の役割が強化されています。
- 本レポートは、提供内容、データソース、ユースケース、エンドユーザー、地域に基づいて、臨床分析市場を調査しています。
- 本レポートでは、市場の成長に影響を与える要因（推進要因、制約要因、機会、課題など）を分析しています。
- 本レポートでは、利害関係者にとっての市場における機会と課題を評価し、市場リーダーの競争環境の詳細を提供しています。
- 本レポートでは、マイクロ市場の成長傾向、見通し、そして世界の臨床分析市場への貢献について調査しています。
- 本レポートでは、5つの主要地域における市場セグメントの収益予測を行っています。
- 本レポートは、既存企業だけでなく新規参入企業や小規模企業にとっても、市場の動向を把握し、シェア拡大に繋げる上で役立ちます。本レポートをご購入いただいた企業は、以下の5つの戦略のいずれか、または組み合わせて活用いただけます。
本レポートでは、以下の点について洞察を提供します。
臨床分析市場の業界マクロダイナミクスに影響を与える主要な推進要因（多様なソースからの医療データによる高度な分析とより深い洞察の促進、保険支払者と医療提供者によるアウトカム指標を用いた集団の健康とケアの質の向上、価値に基づくケアと償還への圧力、クリニックのマクロダイナミクス産業とコンピューティングの急激な発展、クラウドと最新のデータプラットフォームの導入、リアルワールドエビデンス（RWE）に対する規制の開放性、個別化医療とプレシジョン医療への移行、リアルタイムの臨床意思決定の必要性の高まり）、制約要因（データプライバシーと規制上の制約、データ品質と標準化の問題、高い導入コストと不明確なROI）、機会（分散型およびハイブリッド臨床試験向けの分析、遠隔モニタリングのためのエッジおよびオンデバイス分析）、課題（モデル検証と臨床エビデンス、偏ったトレーニングデータ、ベンダーロックインと移行リスク）の分析
- 製品開発／イノベーション：臨床分析市場における今後の技術、研究開発活動、製品投入に関する詳細な洞察。
- 市場開発：収益性の高い新興市場に関する包括的な情報。本レポートでは、様々な地域における臨床分析を分析しています。
- 市場の多様化：臨床分析市場における製品、未開拓地域、最近の動向、投資に関する包括的な情報。
- 競合評価：臨床分析市場における主要企業の市場シェア、戦略、製品、流通ネットワーク、製造能力に関する詳細な評価。
Report Description
The clinical analytics market was valued at USD 33.09 billion in 2025 and is estimated to reach USD 81.32 billion by 2030, registering a CAGR of 19.7% during the forecast period. Market growth is driven by the explosion of clinical data, fueled by the widespread adoption of EHRs, connected medical devices, and remote monitoring solutions, creating a pressing need for advanced analytics capabilities. Advances in AI, machine learning (ML), and high-performance computing are enabling faster and more accurate data processing, unlocking actionable insights from complex datasets. Growing regulatory openness to real-world evidence (RWE) is further accelerating adoption, as healthcare organizations increasingly leverage analytics to support clinical trials, treatment planning, and value-based care models. Additionally, the shift toward personalized and precision medicine is driving demand for patient-specific analytics to optimize diagnostics, treatment selection, and outcomes. The increasing need for real-time clinical decision-making is reinforcing the role of clinical analytics as a critical tool for improving patient safety, reducing errors, and enhancing the overall efficiency of care delivery.
Based on the data source, the EHR segment is expected to record significant growth in the clinical analytics market during the forecast period.
A key driver for the significant growth of the EHR segment in the clinical analytics market is the increasing adoption of electronic health records as the primary source of structured and unstructured patient data used for advanced analytics and decision support. EHR systems capture a wide range of clinical information including patient demographics, medical history, diagnostics, treatment plans, and outcomes—making them a critical foundation for real-time insights and predictive modeling. The rising emphasis on interoperability and standardized data exchange, supported by regulations such as the US 21st Century Cures Act and global digital health initiatives, further accelerates the integration of EHR data into clinical analytics platforms. As healthcare providers and payers increasingly rely on data-driven strategies to improve care quality and operational performance, EHR systems enable more accurate risk stratification, early disease detection, and personalized treatment planning, fueling their strong market growth.
Based on the offering, the raw data segment is expected to hold a significant share in the clinical analytics market for 2024.
Driven by the growing need for comprehensive, high-quality data to support accurate insights and predictive analytics, the raw data segment is expected to hold a significant share in the clinical analytics market for 2024. Raw clinical data from sources such as EHRs, laboratory systems, imaging devices, and patient monitoring tools form the foundation for advanced analytics, enabling healthcare organizations to identify trends, assess population health, and make informed decisions. The increasing adoption of data-driven strategies and initiatives to standardize and integrate diverse healthcare datasets further fuels the demand for raw data as a critical input for analytics platforms.
The Asia Pacific market accounted for the fastest growth in the clinical analytics market for the forecast period.
A key driver for the rapid growth of the Asia Pacific clinical analytics market is the increasing adoption of digital health technologies, including EHRs, telemedicine, and AI-powered analytics solutions, by healthcare providers seeking to improve patient outcomes and operational efficiency. The region is witnessing rising healthcare expenditure, growing government initiatives to promote smart hospitals and healthcare digitization, and expanding investments in health IT infrastructure, particularly in countries like China, India, and Japan. Additionally, the rising prevalence of chronic diseases, aging populations, and a growing focus on value-based care are driving demand for data-driven insights, predictive analytics, and population health management solutions, further accelerating market growth in the Asia Pacific region.
In-depth interviews have been conducted with chief executive officers (CEOs), Directors, and other executives from various key organizations operating in the clinical analytics market.
The breakdown of primary participants is as mentioned below:
- By Company Type – Tier 1 (41%), Tier 2 (31%), and Tier 3 (28%)
- By Designation – C Level (44%), Directors (31%), and Others (25%)
- By Region – North America (45%), Europe (28%), Asia Pacific (20%), Latin America (4%), Middle East & Africa (3%)
Key Players in the Clinical Analytics Market
Prominent players in the clinical analytics market include Optum, Inc. (UnitedHealth Group) (US), Epic Systems Corporation (US), GE HealthCare (US), Siemens Healthineers (Germany), Oracle Health Sciences (US), McKesson Corporation (US), Veradigm LLC (US), IQVIA (US), Cotiviti Inc. (US), Health Catalyst (US), Cognizant (US), Koninklijke Philips N.V. (Netherlands), Dassault Systèmes (France), Athenahealth, Inc. (US), Veeva Systems (US), ICON plc (Ireland), eClinicalWorks (US), Accenture (Ireland), CVS Health (US), Inovalon (US), WNS (Holdings) Ltd. (UK), Merative (US), SOPHiA GENETICS (Switzerland), F. Hoffmann-La Roche Ltd (Roche)(FLATIRON HEALTH) (US), SAS Institute, Inc. (US).
Market players are focusing on organic as well as inorganic growth strategies such as product launches and enhancements, investments, partnerships, collaborations, joint ventures, funding, acquisitions, expansions, agreements, contracts, and alliances to broaden their offerings, cater to the unmet needs of customers, increase profitability, and expand their presence in the global market.
The study includes an in-depth competitive analysis of these key players in the clinical analytics market, with their company profiles, recent developments, and key market strategies.
Research Coverage
- The report studies the clinical analytics market based on offering, data source, use case, end user, and region.
- The report analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting market growth.
- The report evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders.
- The report studies micro-markets with respect to their growth trends, prospects, and contributions to the global clinical analytics market.
- The report forecasts the revenue of market segments with respect to five major regions.
Reasons to Buy the Report
The report can help established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share. Firms purchasing the report could use one or a combination of the following five strategies.
This report provides insights into the following pointers:
Analysis of key drivers (healthcare data from diverse sources fuels advanced analytics and deeper insights, Payers and providers use outcome metrics to enhance population health and care quality, value-based care & reimbursement pressure, explosion of clinic macro dynamic industry and compute, adoption of cloud & modern data platforms, regulatory openness to RWE, shift toward personalized and precision medicine, increasing need for real-time clinical decision-making), restraints (data privacy & regulatory constraints, data quality & standardization issues, high implementation cost & unclear ROI), opportunities (analytics for decentralized & hybrid clinical trials, edge & on-device analytics for remote monitoring), and challenges (model validation & clinical evidence, biased training data, vendor lock in & migration risk.) influencing the industry macro dynamics of clinical analytics market.
- Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and product launches in the clinical analytics market.
- Market Development: Comprehensive information about lucrative emerging markets. The report analyzes clinical analytics across varied regions.
- Market Diversification: Exhaustive information about products, untapped regions, recent developments, and investments in the clinical analytics market.
- Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the clinical analytics market.
Table of Contents
1 INTRODUCTION 36
1.1 STUDY OBJECTIVES 36
1.2 MARKET DEFINITION 36
1.3 MARKET SCOPE 37
1.3.1 MARKET SEGMENTATION AND REGIONAL SCOPE 37
1.3.2 INCLUSIONS AND EXCLUSIONS 38
1.3.3 YEARS CONSIDERED 39
1.4 CURRENCY CONSIDERED 39
1.5 STAKEHOLDERS 40
2 RESEARCH METHODOLOGY 41
2.1 RESEARCH APPROACH 41
2.1.1 SECONDARY RESEARCH 42
2.1.1.1 Key data from secondary sources 43
2.1.2 PRIMARY RESEARCH 43
2.1.2.1 Primary sources 44
2.1.2.2 Key data from primary sources 45
2.1.2.3 Breakdown of primaries 45
2.1.2.4 Insights from primary experts 46
2.2 RESEARCH METHODOLOGY 46
2.3 MARKET SIZE ESTIMATION 47
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 52
2.5 MARKET SHARE ESTIMATION 52
2.6 RESEARCH ASSUMPTIONS 53
2.7 RESEARCH LIMITATIONS 53
2.8 RISK ASSESSMENT 53
3 EXECUTIVE SUMMARY 54
4 PREMIUM INSIGHTS 59
4.1 CLINICAL ANALYTICS MARKET OVERVIEW 59
4.2 CLINICAL ANALYTICS MARKET, BY USE CASE AND REGION 60
4.3 CLINICAL ANALYTICS MARKET: GEOGRAPHIC SNAPSHOT 61
4.4 CLINICAL ANALYTICS MARKET: DEVELOPED VS. EMERGING MARKETS 62
5 MARKET OVERVIEW 63
5.1 INTRODUCTION 63
5.2 MARKET DYNAMICS 64
5.2.1 DRIVERS 65
5.2.1.1 Rapid growth of clinical data 65
5.2.1.2 Ongoing transition from fee-for-service models to value-based care 66
5.2.1.3 Rising advancements in AI/ML and computing capabilities 66
5.2.1.4 Increasing acceptance of real-world evidence 67
5.2.1.5 Growing recognition of social determinants of health 67
5.2.1.6 Rising volume of clinical trials 67
5.2.1.7 Expanding healthcare data 68
5.2.1.8 Increasing use of outcome metrics 68
5.2.2 RESTRAINTS 68
5.2.2.1 Data privacy and regulatory constraints 68
5.2.2.2 Data quality and standardization issues 69
5.2.2.3 High implementation cost and unclear return on investment 69
5.2.2.4 Interoperability gaps and prevalence of legacy IT systems 70
5.2.3 OPPORTUNITIES 70
5.2.3.1 Growing adoption of decentralized and hybrid clinical trial models 70
5.2.3.2 Increasing adoption of edge computing and on-device analytics 70
5.2.3.3 Increasing use of embedded workflow analytics 71
5.2.4 CHALLENGES 71
5.2.4.1 Presence of biased or unrepresentative training data 71
5.2.4.2 Vendor lock-in and migration risk 72
5.2.4.3 Pricing and contracting complexities 72
5.2.4.4 Data governance and provenance issues 73
5.2.4.5 Model validation and clinical evidence challenges 73
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 73
5.4 INDUSTRY TRENDS 74
5.4.1 GENERATIVE AI FOR CLINICAL REASONING 74
5.4.2 REAL-WORLD EVIDENCE AND DECENTRALIZED TRIALS 74
5.4.3 VALUE-BASED CARE AND POPULATION HEALTH ANALYTICS 74
5.5 PRICING ANALYSIS 75
5.5.1 INDICATIVE PRICING ANALYSIS, BY KEY PLAYER 75
5.5.2 INDICATIVE PRICING ANALYSIS, BY REGION 76
5.5.3 QUALITATIVE PRICING MODELS 77
5.6 SUPPLY CHAIN ANALYSIS 79
5.7 ECOSYSTEM ANALYSIS 81
5.8 INVESTMENT AND FUNDING SCENARIO 84
5.9 TECHNOLOGY ANALYSIS 84
5.9.1 KEY TECHNOLOGIES 85
5.9.1.1 Predictive analytics and risk stratification 85
5.9.1.2 Health Information Exchange (HIE) platforms 85
5.9.1.3 Clinical Decision Support Systems (CDSS) 85
5.9.1.4 Machine Learning (ML) and Deep Learning (DL) 85
5.9.1.5 Natural Language Processing (NLP) 86
5.9.1.6 Data visualization & business intelligence tools 86
5.9.2 COMPLEMENTARY TECHNOLOGIES 87
5.9.2.1 Blockchain 87
5.9.2.2 Internet of Medical Things (IoMT) 87
5.9.2.3 Robotic Process Automation (RPA) 87
5.9.2.4 FHIR/HL7 Interoperability Standards 87
5.9.2.5 Digital twin technology 88
5.9.3 ADJACENT TECHNOLOGIES 88
5.9.3.1 Virtual clinical trial platforms 88
5.9.3.2 Digital Therapeutics (DTx) 88
5.10 PATENT ANALYSIS 89
5.10.1 PATENT PUBLICATION TRENDS 89
5.10.2 JURISDICTION AND TOP APPLICANT ANALYSIS 89
5.11 KEY CONFERENCES AND EVENTS, 2025–2026 93
5.12 CASE STUDY ANALYSIS 94
5.12.1 ENHANCED PATIENT FLOW AND REDUCED EMERGENCY DEPARTMENT CONGESTION USING REAL-TIME OPERATIONAL ANALYTICS 94
5.12.2 IMPROVED GENOMIC DATA INTERPRETATION THROUGH AI-POWERED GENOMIC ANALYTICS 94
5.12.3 ENHANCED PROVIDER PERFORMANCE USING ADVANCED CLINICAL ANALYTICS 95
5.12.4 OPTIMIZING CARE DELIVERY THROUGH PREDICTIVE MODEL INTEGRATION 95
5.13 REGULATORY LANDSCAPE 96
5.13.1 REGULATORY ANALYSIS 96
5.13.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 101
5.14 PORTER’S FIVE FORCES ANALYSIS 104
5.14.1 BARGAINING POWER OF SUPPLIERS 105
5.14.2 BARGAINING POWER OF BUYERS 105
5.14.3 THREAT OF NEW ENTRANTS 105
5.14.4 THREAT OF SUBSTITUTES 106
5.14.5 INTENSITY OF COMPETITIVE RIVALRY 106
5.15 KEY STAKEHOLDERS AND BUYING CRITERIA 106
5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS 107
5.15.2 BUYING CRITERIA 108
5.16 END-USER ANALYSIS 108
5.16.1 UNMET NEEDS 108
5.16.2 END-USER EXPECTATIONS 110
5.17 BUSINESS MODEL ANALYSIS 111
5.17.1 LICENSE-BASED BUSINESS MODEL 111
5.17.2 SUBSCRIPTION-BASED BUSINESS MODEL 111
5.17.3 SOFTWARE-AS-A-SERVICE (SAAS) BUSINESS MODEL 112
5.17.4 PAY-PER-USE BUSINESS MODEL 112
5.17.5 FREEMIUM BUSINESS MODEL 112
5.17.6 INTEGRATED SERVICE AND SOFTWARE BUNDLE BUSINESS MODEL 112
5.17.7 OUTCOME-BASED OR VALUE-BASED BUSINESS MODEL 112
5.17.8 SOFTWARE AS A MEDICAL DEVICE (SAMD) BUSINESS MODEL 113
5.18 IMPACT OF AI/GEN AI ON CLINICAL ANALYTICS MARKET 113
5.18.1 INTRODUCTION 113
5.18.2 MARKET POTENTIAL OF AI IN CLINICAL ANALYTICS ECOSYSTEM 113
5.18.3 KEY USE CASES 114
5.18.4 AI CASE STUDY 116
5.18.4.1 Case Study 1: AI-powered analytics platform for patient satisfaction 116
5.18.4.2 Case Study 2: Next-generation predictive modelling solution for operational efficiency 116
5.18.5 IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS 117
5.18.5.1 AI in patient engagement & support platforms 118
5.18.5.2 AI in healthcare operations & management tools 118
5.18.5.3 AI in personalized health & wellness coaching 118
5.18.6 USER READINESS AND IMPACT ASSESSMENT 118
5.18.6.1 User readiness 118
5.18.6.1.1 User A: Healthcare providers 118
5.18.6.1.2 User B: Healthcare payers 118
5.18.6.1.3 User C: Life science companies 119
5.18.6.2 Impact assessment 119
5.18.6.2.1 User A: Healthcare providers 119
5.18.6.2.1.1 Implementation 119
5.18.6.2.1.2 Impact 119
5.18.6.2.2 User B: Healthcare payers 120
5.18.6.2.2.1 Implementation 120
5.18.6.2.2.2 Impact 120
5.18.6.2.3 User C: Life sciences 120
5.18.6.2.3.1 Implementation 120
5.18.6.2.3.2 Impact 121
5.19 IMPACT OF 2025 US TARIFFS ON CLINICAL ANALYTICS MARKET 121
5.19.1 INTRODUCTION 121
5.19.2 KEY TARIFF RATES 122
5.19.3 PRICE IMPACT ANALYSIS 123
5.19.4 IMPACT ON COUNTRY/REGION 125
5.19.4.1 US 125
5.19.4.2 Europe 126
5.19.4.3 Asia Pacific 126
5.19.5 IMPACT ON END-USE INDUSTRIES 126
6 CLINICAL ANALYTICS MARKET, BY OFFERING 128
6.1 INTRODUCTION 129
6.2 RAW DATA 129
6.2.1 NEED FOR REAL-WORLD EVIDENCE, OUTCOMES,
AND RESEARCH TO DRIVE MARKET 129
6.3 SOFTWARE 130
6.3.1 IMPROVED CLINICAL, OPERATIONAL, AND FINANCIAL
INTELLIGENCE TO BOOST MARKET 130
6.4 PLATFORM 131
6.4.1 INCREASING DIGITIZATION OF HEALTHCARE SYSTEMS TO FUEL MARKET 131
7 CLINICAL ANALYTICS MARKET, BY DATA SOURCE 133
7.1 INTRODUCTION 134
7.2 CLINICAL TRIALS DATA 134
7.2.1 ABILITY TO PROVIDE ROBUST, STRUCTURED, AND
HIGH-QUALITY INFORMATION TO CONTRIBUTE TO GROWTH 134
7.3 CLAIMS DATA 136
7.3.1 INCREASING USE OF CLAIMS DATA BY HEALTHCARE
INSTITUTIONS AND PAYERS TO EXPEDITE GROWTH 136
7.4 ELECTRONIC HEALTH RECORDS 137
7.4.1 RISING FOCUS ON PATIENT OUTCOMES, RISK STRATIFICATION, AND EARLY DETECTION OF CLINICAL DETERIORATION TO AID GROWTH 137
7.5 REGISTRIES & RWE 138
7.5.1 GROWING EMPHASIS VALUE-BASED CARE, PERSONALIZED TREATMENT, AND REGULATORY COMPLIANCE TO DRIVE MARKET 138
7.6 IMAGING & DIAGNOSTICS 140
7.6.1 RISING DEMAND FOR PRECISION DIAGNOSTICS AND EVIDENCE-BASED TREATMENT PLANNING TO PROMOTE GROWTH 140
7.7 LAB & PATHOLOGY 141
7.7.1 INCREASING USE OF HIGH-THROUGHPUT TECHNOLOGIES TO SPUR GROWTH 141
7.8 MULTIOMICS DATA 143
7.8.1 RAPID ADVANCEMENT OF NEXT-GENERATION SEQUENCING, MASS SPECTROMETRY, AND SINGLE-CELL TECHNOLOGIES TO FAVOR GROWTH 143
7.9 OTHER DATA SOURCES 144
8 CLINICAL ANALYTICS MARKET, BY USE CASE 146
8.1 INTRODUCTION 147
8.2 HEALTHCARE USE CASES 147
8.2.1 CLINICAL DECISION SUPPORT 149
8.2.1.1 Growing complexity of patient care and rising prevalence of chronic diseases to drive market 149
8.2.2 POPULATION HEALTH & RISK STRATIFICATION 150
8.2.2.1 Ability to drive proactive, preventive care to facilitate growth 150
8.2.3 QUALITY COMPLIANCE & REPORTING 152
8.2.3.1 Rising focus on enhancing integrity, transparency, and regulatory adherence to support growth 152
8.2.4 OPERATIONAL & CAPACITY ANALYTICS 153
8.2.4.1 Growing focus on optimized healthcare services to fuel market 153
8.2.5 REMOTE PATIENT MONITORING 154
8.2.5.1 Need for continuous data-driven patient care to spur growth 154
8.2.6 OTHER HEALTHCARE USE CASES 156
8.3 LIFE SCIENCE USE CASES 157
8.3.1 R&D & CLINICAL DEVELOPMENT 159
8.3.1.1 Increasing adoption of predictive modeling and simulation tools to aid growth 159
8.3.2 SAFETY & PHARMACOVIGILANCE 160
8.3.2.1 Enhanced drug safety to contribute to growth 160
8.3.3 PRECISION & TRANSLATIONAL CLINICAL ANALYTICS 162
8.3.3.1 Ability to drive precision medicine through data-driven translational insights to favor growth 162
8.3.4 REGULATORY EVIDENCE ANALYTICS 163
8.3.4.1 Evolving regulatory landscape to bolster growth 163
8.3.5 HEOR & RWE ANALYTICS 165
8.3.5.1 Increasing strategic collaborations and technological innovations to boost market 165
8.3.6 OTHER LIFE SCIENCE USE CASES 166
9 CLINICAL ANALYTICS MARKET, BY END USER 168
9.1 INTRODUCTION 169
9.2 HEALTHCARE PROVIDERS 169
9.2.1 HOSPITALS & CLINICS 171
9.2.1.1 Increasing adoption of clinical analytics in hospitals and clinics to support growth 171
9.2.2 AMBULATORY CARE SERVICES 172
9.2.2.1 Need to improve quality outcomes and reduce avoidable hospital admissions to foster growth 172
9.2.3 DIAGNOSTIC CENTERS 173
9.2.3.1 Rising shift toward precision medicine and value-based care models to stimulate growth 173
9.2.4 SPECIALTY PRACTICE PROVIDERS 174
9.2.4.1 Growing prevalence of chronic and complex diseases care to boost market 174
9.2.5 OTHER HEALTHCARE PROVIDERS 175
9.3 HEALTHCARE PAYERS 176
9.3.1 NEED TO IMPROVE RETURN ON INVESTMENT TO ENCOURAGE GROWTH 176
9.4 LIFE SCIENCES 177
9.4.1 PHARMACEUTICALS & BIOTECH COMPANIES 179
9.4.1.1 Increasing complexity of therapeutic development to augment growth 179
9.4.2 MEDTECH COMPANIES 180
9.4.2.1 Need to accelerate product development cycles and economic value to propel market 180
9.4.3 OTHER LIFE SCIENCE END USERS 181
9.5 OTHER END USERS 182
10 CLINICAL ANALYTICS MARKET, BY REGION 184
10.1 INTRODUCTION 185
10.2 NORTH AMERICA 186
10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 186
10.2.2 US 192
10.2.2.1 Growing advancements in machine learning, predictive modeling, and natural language processing to drive market 192
10.2.3 CANADA 197
10.2.3.1 Increasing prevalence of chronic diseases and accelerated digital transformation in healthcare to fuel market 197
10.3 EUROPE 201
10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 202
10.3.2 GERMANY 208
10.3.2.1 Comprehensive digital health policy framework and significant federal investment in healthcare modernization to aid growth 208
10.3.3 FRANCE 212
10.3.3.1 Strong commitment to digital health transformation and robust institutional research ecosystem to foster growth 212
10.3.4 UK 216
10.3.4.1 Favorable investments and digital health strategy to contribute to growth 216
10.3.5 ITALY 221
10.3.5.1 Increasing emphasis on digital health record systems and healthcare research to stimulate growth 221
10.3.6 SPAIN 226
10.3.6.1 Growing public investment in data-driven healthcare and national mental health strategies to boost market 226
10.3.7 REST OF EUROPE 230
10.4 ASIA PACIFIC 235
10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 235
10.4.2 CHINA 242
10.4.2.1 Rising focus on modernizing healthcare delivery and enhancing patient outcomes to expedite growth 242
10.4.3 JAPAN 247
10.4.3.1 Booming geriatric population and advanced technological ecosystem to amplify growth 247
10.4.4 INDIA 251
10.4.4.1 Rapid adoption of electronic health records to accelerate growth 251
10.4.5 SOUTH KOREA 256
10.4.5.1 Increasing prevalence of chronic and lifestyle-related conditions to aid growth 256
10.4.6 REST OF ASIA PACIFIC 261
10.5 LATIN AMERICA 266
10.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 266
10.5.2 BRAZIL 271
10.5.2.1 Rising integration of AI-driven analytics in healthcare systems to encourage growth 271
10.5.3 MEXICO 276
10.5.3.1 Rising burden of non-communicable diseases to facilitate growth 276
10.5.4 REST OF LATIN AMERICA 281
10.6 MIDDLE EAST & AFRICA 285
10.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 286
10.6.2 GCC COUNTRIES 291
10.6.2.1 Saudi Arabia 296
10.6.2.1.1 Growing adoption of electronic health records and centralized digital platforms to fuel market 296
10.6.2.2 UAE 300
10.6.2.2.1 Favorable policy and regulatory environment to promote growth 300
10.6.2.3 Rest of GCC Countries 304
10.6.3 SOUTH AFRICA 309
10.6.3.1 Robust public and private health systems to facilitate growth 309
10.6.4 REST OF MIDDLE EAST & AFRICA 313
11 COMPETITIVE LANDSCAPE 319
11.1 OVERVIEW 319
11.2 STRATEGIES ADOPTED BY KEY PLAYERS 319
11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN CLINICAL ANALYTICS MARKET 320
11.3 REVENUE ANALYSIS, 2020–2024 322
11.4 MARKET SHARE ANALYSIS, 2024 323
11.5 MARKET RANKING ANALYSIS 326
11.6 COMPANY VALUATION AND FINANCIAL METRICS 327
11.7 BRAND/PRODUCT COMPARISON 329
11.8 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 330
11.8.1 STARS 330
11.8.2 EMERGING LEADERS 330
11.8.3 PERVASIVE PLAYERS 330
11.8.4 PARTICIPANTS 330
11.8.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 332
11.8.5.1 Company footprint 332
11.8.5.2 Region footprint 333
11.8.5.3 Offering footprint 334
11.8.5.4 Data source footprint 335
11.8.5.5 Use case footprint 336
11.8.5.6 End-user footprint 337
11.9 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 338
11.9.1 PROGRESSIVE COMPANIES 338
11.9.2 RESPONSIVE COMPANIES 338
11.9.3 DYNAMIC COMPANIES 338
11.9.4 STARTING BLOCKS 338
11.9.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024 340
11.9.5.1 Detailed list of key startups/SMEs 340
11.9.5.2 Competitive benchmarking of startups/SMEs 340
11.10 COMPETITIVE SCENARIO 341
11.10.1 PRODUCT LAUNCHES AND APPROVALS 341
11.10.2 DEALS 342
11.10.3 OTHER DEVELOPMENTS 343
12 COMPANY PROFILES 344
12.1 KEY PLAYERS 344
12.1.1 IQVIA 344
12.1.1.1 Business overview 344
12.1.1.2 Products offered 346
12.1.1.3 Recent developments 347
12.1.1.3.1 Product launches and approvals 347
12.1.1.3.2 Deals 349
12.1.1.4 MnM view 350
12.1.1.4.1 Right to win 350
12.1.1.4.2 Strategic choices 350
12.1.1.4.3 Weaknesses and competitive threats 351
12.1.2 OPTUM, INC. 352
12.1.2.1 Business overview 352
12.1.2.2 Products offered 353
12.1.2.3 Recent developments 355
12.1.2.3.1 Product launches and approvals 355
12.1.2.3.2 Deals 356
12.1.2.4 MnM view 357
12.1.2.4.1 Right to win 357
12.1.2.4.2 Strategic choices 357
12.1.2.4.3 Weaknesses and competitive threats 357
12.1.3 MERATIVE 358
12.1.3.1 Business overview 358
12.1.3.2 Products offered 359
12.1.3.3 Recent developments 360
12.1.3.3.1 Deals 360
12.1.3.4 MnM view 360
12.1.3.4.1 Right to win 360
12.1.3.4.2 Strategic choices 361
12.1.3.4.3 Weaknesses and competitive threats 361
12.1.4 EPIC SYSTEMS CORPORATION 362
12.1.4.1 Business overview 362
12.1.4.2 Products offered 363
12.1.4.3 Recent developments 364
12.1.4.3.1 Product launches and approvals 364
12.1.4.3.2 Deals 365
12.1.4.4 MnM view 366
12.1.4.4.1 Right to win 366
12.1.4.4.2 Strategic choices 367
12.1.4.4.3 Weaknesses and competitive threats 367
12.1.5 GE HEALTHCARE 368
12.1.5.1 Business overview 368
12.1.5.2 Products offered 370
12.1.5.3 Recent developments 371
12.1.5.3.1 Product launches and approvals 371
12.1.5.3.2 Deals 372
12.1.5.3.3 Other developments 373
12.1.5.4 MnM view 373
12.1.5.4.1 Right to win 373
12.1.5.4.2 Strategic choices 374
12.1.5.4.3 Weaknesses and competitive threats 374
12.1.6 SIEMENS HEALTHINEERS AG 375
12.1.6.1 Business overview 375
12.1.6.2 Products offered 377
12.1.6.3 Recent developments 378
12.1.6.3.1 Product launches and approvals 378
12.1.6.3.2 Deals 379
12.1.6.3.3 Other developments 381
12.1.6.4 MnM view 381
12.1.6.4.1 Right to win 381
12.1.6.4.2 Strategic choices 381
12.1.7 ORACLE 383
12.1.7.1 Business overview 383
12.1.7.2 Products offered 385
12.1.7.3 Recent developments 387
12.1.7.3.1 Product launches and approvals 387
12.1.7.3.2 Deals 388
12.1.7.4 MnM view 389
12.1.7.4.1 Right to win 389
12.1.7.4.2 Strategic choices 389
12.1.7.4.3 Weaknesses and competitive threats 389
12.1.8 MCKESSON CORPORATION 390
12.1.8.1 Business overview 390
12.1.8.2 Products offered 391
12.1.8.3 Recent developments 393
12.1.8.3.1 Product launches and approvals 393
12.1.8.3.2 Deals 394
12.1.8.3.3 Other developments 395
12.1.9 VERADIGM LLC 396
12.1.9.1 Business overview 396
12.1.9.2 Products offered 398
12.1.9.3 Recent developments 399
12.1.9.3.1 Product launches and approvals 399
12.1.9.3.2 Deals 401
12.1.9.3.3 Other developments 402
12.1.10 INOVALON 403
12.1.10.1 Business overview 403
12.1.10.2 Products offered 404
12.1.10.3 Recent developments 405
12.1.10.3.1 Product launches and approvals 405
12.1.10.3.2 Deals 406
12.1.11 WNS (HOLDINGS) LTD. 407
12.1.11.1 Business overview 407
12.1.11.2 Products offered 409
12.1.11.3 Recent developments 410
12.1.11.3.1 Deals 410
12.1.11.3.2 Other developments 411
12.1.12 SOPHIA GENETICS 412
12.1.12.1 Business overview 412
12.1.12.2 Products offered 413
12.1.12.3 Recent developments 414
12.1.12.3.1 Product launches and approvals 414
12.1.12.3.2 Deals 415
12.1.13 COTIVITI, INC. 416
12.1.13.1 Business overview 416
12.1.13.2 Products offered 417
12.1.13.3 Recent developments 418
12.1.13.3.1 Product launches and approvals 418
12.1.13.3.2 Deals 419
12.1.14 HEALTH CATALYST 420
12.1.14.1 Business overview 420
12.1.14.2 Products offered 421
12.1.14.3 Recent developments 423
12.1.14.3.1 Product launches and approvals 423
12.1.14.3.2 Deals 424
12.1.15 COGNIZANT 425
12.1.15.1 Business overview 425
12.1.15.2 Products offered 427
12.1.15.3 Recent developments 428
12.1.15.3.1 Product launches and approvals 428
12.1.15.3.2 Deals 429
12.1.16 F. HOFFMANN-LA ROCHE LTD 430
12.1.16.1 Business overview 430
12.1.16.2 Products offered 432
12.1.16.3 Recent developments 433
12.1.16.3.1 Product launches and approvals 433
12.1.16.3.2 Deals 434
12.1.17 KONINKLIJKE PHILIPS N.V. 436
12.1.17.1 Business overview 436
12.1.17.2 Products offered 438
12.1.17.3 Recent developments 439
12.1.17.3.1 Product launches and approvals 439
12.1.17.3.2 Deals 440
12.1.18 DASSAULT SYSTÈMES (MEDIDATA) 441
12.1.18.1 Business overview 441
12.1.18.2 Products offered 443
12.1.18.3 Recent developments 444
12.1.18.3.1 Product launches and approvals 444
12.1.18.3.2 Deals 446
12.1.19 ATHENAHEALTH, INC. 451
12.1.19.1 Business overview 451
12.1.19.2 Products offered 452
12.1.19.3 Recent developments 453
12.1.19.3.1 Product launches and approvals 453
12.1.19.3.2 Deals 454
12.1.20 VEEVA SYSTEMS 455
12.1.20.1 Business overview 455
12.1.20.2 Products offered 457
12.1.20.3 Recent developments 458
12.1.20.3.1 Product launches and approvals 458
12.1.20.3.2 Deals 460
12.1.21 ICON PLC 463
12.1.21.1 Business overview 463
12.1.21.2 Products offered 464
12.1.21.3 Recent developments 465
12.1.21.3.1 Product launches and approvals 465
12.1.21.3.2 Deals 466
12.1.22 ECLINICALWORKS 467
12.1.22.1 Business overview 467
12.1.22.2 Products offered 468
12.1.22.3 Recent developments 469
12.1.22.3.1 Product launches and approvals 469
12.1.22.3.2 Deals 470
12.1.23 ACCENTURE 471
12.1.23.1 Business overview 471
12.1.23.2 Products offered 473
12.1.23.3 Recent developments 474
12.1.23.3.1 Deals 474
12.1.24 CVS HEALTH 475
12.1.24.1 Business overview 475
12.1.24.2 Products offered 476
12.1.24.3 Recent developments 477
12.1.24.3.1 Product launches and approvals 477
12.1.24.3.2 Deals 478
12.1.25 SAS INSTITUTE INC. 479
12.1.25.1 Business overview 479
12.1.25.2 Products offered 480
12.1.25.3 Recent developments 481
12.1.25.3.1 Product launches and approvals 481
12.1.25.3.2 Deals 482
12.2 OTHER PLAYERS 483
12.2.1 APRIQOT 483
12.2.2 OLER HEALTH 484
12.2.3 PERCIPIO HEALTH 485
12.2.4 FERRUM HEALTH 485
12.2.5 AMPLIFY HEALTH 486
13 APPENDIX 487
13.1 DISCUSSION GUIDE 487
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 491
13.3 CUSTOMIZATION OPTIONS 493
13.4 RELATED REPORTS 494
13.5 AUTHOR DETAILS 494
LIST OF TABLES
TABLE 1 CLINICAL ANALYTICS MARKET: INCLUSIONS AND EXCLUSIONS 38
TABLE 2 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD, 2022–2025 40
TABLE 3 CLINICAL ANALYTICS MARKET: RISK ASSESSMENT 53
TABLE 4 CLINICAL ANALYTICS MARKET: IMPACT ANALYSIS 64
TABLE 5 INDICATIVE PRICE OF CLINICAL ANALYTICS SOLUTIONS,
BY KEY PLAYER, 2024 (USD) 76
TABLE 6 INDICATIVE PRICE OF CLINICAL ANALYTICS SOFTWARE (USD) 76
TABLE 7 INDICATIVE PRICE OF CLINICAL ANALYTICS SOLUTIONS, BY REGION, 2024 (USD) 77
TABLE 8 CLINICAL ANALYTICS MARKET: ROLE OF COMPANIES IN ECOSYSTEM 83
TABLE 9 CLINICAL ANALYTICS MARKET: KEY TECHNOLOGIES 86
TABLE 10 JURISDICTION ANALYSIS OF TOP APPLICANT COUNTRIES FOR
CLINICAL ANALYTICS SOLUTIONS 90
TABLE 11 CLINICAL ANALYTICS MARKET: LIST OF PATENTS/PATENT APPLICATIONS 92
TABLE 12 CLINICAL ANALYTICS MARKET: KEY CONFERENCES AND EVENTS, 2025–2026 93
TABLE 13 REGULATORY REQUIREMENTS IN NORTH AMERICA 96
TABLE 14 REGULATORY REQUIREMENTS IN EUROPE 97
TABLE 15 REGULATORY REQUIREMENTS IN ASIA PACIFIC 98
TABLE 16 REGULATORY REQUIREMENTS IN LATIN AMERICA 99
TABLE 17 REGULATORY REQUIREMENTS IN MIDDLE EAST & AFRICA 100
TABLE 18 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 101
TABLE 19 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 102
TABLE 20 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 102
TABLE 21 REGULATORY STANDARDS IN CLINICAL ANALYTICS MARKET 103
TABLE 22 CLINICAL ANALYTICS MARKET: PORTER’S FIVE FORCES ANALYSIS 105
TABLE 23 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS (%) 107
TABLE 24 KEY BUYING CRITERIA, BY END USER 108
TABLE 25 UNMET NEEDS IN CLINICAL ANALYTICS MARKET 109
TABLE 26 END-USER EXPECTATIONS IN CLINICAL ANALYTICS MARKET 110
TABLE 27 US ADJUSTED RECIPROCAL TARIFF RATES 122
TABLE 28 CLINICAL ANALYTICS MARKET, BY OFFERING, 2023–2030 (USD MILLION) 129
TABLE 29 CLINICAL ANALYTICS PRODUCTS FOR RAW DATA OFFERED BY MAJOR PLAYERS 130
TABLE 30 CLINICAL ANALYTICS MARKET FOR RAW DATA, BY REGION,
2023–2030 (USD MILLION) 130
TABLE 31 CLINICAL ANALYTICS SOFTWARE OFFERED BY MAJOR PLAYERS 131
TABLE 32 CLINICAL ANALYTICS MARKET FOR SOFTWARE, BY REGION,
2023–2030 (USD MILLION) 131
TABLE 33 CLINICAL ANALYTICS PLATFORMS OFFERED BY MAJOR PLAYERS 132
TABLE 34 CLINICAL ANALYTICS MARKET FOR PLATFORM, BY REGION,
2023–2030 (USD MILLION) 132
TABLE 35 CLINICAL ANALYTICS MARKET, BY DATA SOURCE, 2023–2030 (USD MILLION) 134
TABLE 36 CLINICAL ANALYTICS PRODUCTS FOR CLINICAL TRIALS DATA OFFERED
BY MAJOR PLAYERS 135
TABLE 37 CLINICAL ANALYTICS MARKET FOR CLINICAL TRIALS DATA, BY REGION,
2023–2030 (USD MILLION) 135
TABLE 38 CLINICAL ANALYTICS PRODUCTS FOR CLAIMS DATA OFFERED BY MAJOR PLAYERS 136
TABLE 39 CLINICAL ANALYTICS MARKET FOR CLAIMS DATA, BY REGION,
2023–2030 (USD MILLION) 137
TABLE 40 CLINICAL ANALYTICS PRODUCTS FOR EHR OFFERED BY MAJOR PLAYERS 138
TABLE 41 CLINICAL ANALYTICS MARKET FOR EHR, BY REGION, 2023–2030 (USD MILLION) 138
TABLE 42 CLINICAL ANALYTICS PRODUCTS FOR REGISTRIES & RWE OFFERED
BY MAJOR PLAYERS 139
TABLE 43 CLINICAL ANALYTICS MARKET FOR REGISTRIES & RWE, BY REGION,
2023–2030 (USD MILLION) 140
TABLE 44 CLINICAL ANALYTICS PRODUCTS FOR IMAGING & DIAGNOSTICS OFFERED
BY MAJOR PLAYERS 141
TABLE 45 CLINICAL ANALYTICS MARKET FOR IMAGING & DIAGNOSTICS, BY REGION,
2023–2030 (USD MILLION) 141
TABLE 46 CLINICAL ANALYTICS PRODUCTS FOR LAB & PATHOLOGY OFFERED
BY MAJOR PLAYERS 142
TABLE 47 CLINICAL ANALYTICS MARKET FOR LAB & PATHOLOGY, BY REGION,
2023–2030 (USD MILLION) 142
TABLE 48 CLINICAL ANALYTICS PRODUCTS FOR MULTIOMICS DATA OFFERED BY MAJOR PLAYERS 143
TABLE 49 CLINICAL ANALYTICS MARKET FOR MULTIOMICS DATA, BY REGION,
2023–2030 (USD MILLION) 144
TABLE 50 CLINICAL ANALYTICS PRODUCTS FOR OTHER DATA SOURCES OFFERED
BY MAJOR PLAYERS 145
TABLE 51 CLINICAL ANALYTICS MARKET FOR OTHER DATA SOURCES, BY REGION,
2023–2030 (USD MILLION) 145
TABLE 52 CLINICAL ANALYTICS MARKET, BY USE CASE, 2023–2030 (USD MILLION) 147
TABLE 53 CLINICAL ANALYTICS PRODUCTS FOR HEALTHCARE USE CASES OFFERED
BY MAJOR PLAYERS 148
TABLE 54 CLINICAL ANALYTICS MARKET FOR HEALTHCARE USE CASES, BY TYPE,
2023–2030 (USD MILLION) 148
TABLE 55 CLINICAL ANALYTICS MARKET FOR HEALTHCARE USE CASES, BY REGION,
2023–2030 (USD MILLION) 149
TABLE 56 CLINICAL ANALYTICS MARKET FOR CLINICAL DECISION SUPPORT, BY REGION, 2023–2030 (USD MILLION) 150
TABLE 57 CLINICAL ANALYTICS MARKET FOR POPULATION HEALTH & RISK STRATIFICATION, BY REGION, 2023–2030 (USD MILLION) 151
TABLE 58 CLINICAL ANALYTICS MARKET FOR QUALITY COMPLIANCE & REPORTING,
BY REGION, 2023–2030 (USD MILLION) 153
TABLE 59 CLINICAL ANALYTICS MARKET FOR OPERATIONAL & CAPACITY ANALYTICS,
BY REGION, 2023–2030 (USD MILLION) 154
TABLE 60 CLINICAL ANALYTICS MARKET FOR REMOTE PATIENT MONITORING,
BY REGION, 2023–2030 (USD MILLION) 155
TABLE 61 CLINICAL ANALYTICS MARKET FOR OTHER USE CASES, BY REGION,
2023–2030 (USD MILLION) 157
TABLE 62 CLINICAL ANALYTICS PRODUCTS FOR LIFE SCIENCE USE CASES
BY MAJOR PLAYERS 158
TABLE 63 CLINICAL ANALYTICS MARKET FOR LIFE SCIENCE USE CASES, BY TYPE,
2023–2030 (USD MILLION) 158
TABLE 64 CLINICAL ANALYTICS MARKET FOR LIFE SCIENCE USE CASES, BY REGION,
2023–2030 (USD MILLION) 159
TABLE 65 CLINICAL ANALYTICS MARKET FOR R&D & CLINICAL DEVELOPMENT, BY REGION, 2023–2030 (USD MILLION) 160
TABLE 66 CLINICAL ANALYTICS MARKET FOR SAFETY & PHARMACOVIGILANCE, BY REGION, 2023–2030 (USD MILLION) 161
TABLE 67 CLINICAL ANALYTICS MARKET FOR PRECISION & TRANSLATIONAL CLINICAL ANALYTICS, BY REGION, 2023–2030 (USD MILLION) 163
TABLE 68 CLINICAL ANALYTICS MARKET FOR REGULATORY EVIDENCE ANALYTICS,
BY REGION, 2023–2030 (USD MILLION) 164
TABLE 69 CLINICAL ANALYTICS MARKET FOR HEOR & RWE ANALYTICS, BY REGION,
2023–2030 (USD MILLION) 166
TABLE 70 CLINICAL ANALYTICS MARKET FOR OTHER LIFE SCIENCE USE CASES,
BY REGION, 2023–2030 (USD MILLION) 167
TABLE 71 CLINICAL ANALYTICS MARKET, BY END USER, 2023–2030 (USD MILLION) 169
TABLE 72 CLINICAL ANALYTICS PRODUCTS FOR HEALTHCARE PROVIDERS OFFERED
BY MAJOR PLAYERS 170
TABLE 73 CLINICAL ANALYTICS MARKET FOR BY HEALTHCARE PROVIDERS, BY TYPE,
2023–2030 (USD MILLION) 170
TABLE 74 CLINICAL ANALYTICS MARKET FOR HEALTHCARE PROVIDERS, BY REGION,
2023–2030 (USD MILLION) 171
TABLE 75 CLINICAL ANALYTICS MARKET FOR HOSPITALS & CLINICS, BY REGION,
2023–2030 (USD MILLION) 172
TABLE 76 CLINICAL ANALYTICS MARKET FOR AMBULATORY CARE SERVICES, BY REGION, 2023–2030 (USD MILLION) 173
TABLE 77 CLINICAL ANALYTICS MARKET FOR DIAGNOSTIC CENTERS, BY REGION,
2023–2030 (USD MILLION) 174
TABLE 78 CLINICAL ANALYTICS MARKET FOR SPECIALTY PRACTICE PROVIDERS, BY REGION, 2023–2030 (USD MILLION) 175
TABLE 79 CLINICAL ANALYTICS MARKET FOR OTHER HEALTHCARE PROVIDERS, BY REGION, 2023–2030 (USD MILLION) 176
TABLE 80 CLINICAL ANALYTICS PRODUCTS FOR HEALTHCARE PAYERS OFFERED
BY MAJOR PLAYERS 177
TABLE 81 CLINICAL ANALYTICS MARKET FOR HEALTHCARE PAYERS, BY REGION,
2023–2030 (USD MILLION) 177
TABLE 82 CLINICAL ANALYTICS PRODUCTS FOR LIFE SCIENCES OFFERED BY MAJOR PLAYERS 178
TABLE 83 CLINICAL ANALYTICS MARKET FOR LIFE SCIENCES, BY TYPE,
2023–2030 (USD MILLION) 178
TABLE 84 CLINICAL ANALYTICS MARKET FOR LIFE SCIENCES, BY REGION,
2023–2030 (USD MILLION) 179
TABLE 85 CLINICAL ANALYTICS MARKET FOR PHARMACEUTICAL & BIOTECH COMPANIES,
BY REGION, 2023–2030 (USD MILLION) 180
TABLE 86 CLINICAL ANALYTICS MARKET FOR MEDTECH COMPANIES, BY REGION,
2023–2030 (USD MILLION) 181
TABLE 87 CLINICAL ANALYTICS MARKET FOR OTHER LIFE SCIENCE END USERS,
BY REGION, 2023–2030 (USD MILLION) 182
TABLE 88 CLINICAL ANALYTICS PRODUCTS FOR OTHER END USERS OFFERED
BY MAJOR PLAYERS 183
TABLE 89 CLINICAL ANALYTICS MARKET FOR OTHER END USERS, BY REGION,
2023–2030 (USD MILLION) 183
TABLE 90 CLINICAL ANALYTICS MARKET, BY REGION, 2023–2030 (USD MILLION) 185
TABLE 91 NORTH AMERICA: MACROECONOMIC OUTLOOK 187
TABLE 92 NORTH AMERICA: CLINICAL ANALYTICS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 188
TABLE 93 NORTH AMERICA: CLINICAL ANALYTICS MARKET, BY OFFERING,
2023–2030 (USD MILLION) 189
TABLE 94 NORTH AMERICA: CLINICAL ANALYTICS MARKET, BY DATA SOURCE,
2023–2030 (USD MILLION) 189
TABLE 95 NORTH AMERICA: CLINICAL ANALYTICS MARKET, BY USE CASE,
2023–2030 (USD MILLION) 190
TABLE 96 NORTH AMERICA: CLINICAL ANALYTICS MARKET FOR HEALTHCARE USE CASES,
BY TYPE, 2023–2030 (USD MILLION) 190
TABLE 97 NORTH AMERICA: CLINICAL ANALYTICS MARKET FOR LIFE SCIENCE USE CASES,
BY TYPE, 2023–2030 (USD MILLION) 191
TABLE 98 NORTH AMERICA: CLINICAL ANALYTICS MARKET, BY END USER,
2023–2030 (USD MILLION) 191
TABLE 99 NORTH AMERICA: CLINICAL ANALYTICS MARKET FOR HEALTHCARE PROVIDERS,
BY TYPE, 2023–2030 (USD MILLION) 192
TABLE 100 NORTH AMERICA: CLINICAL ANALYTICS MARKET FOR LIFE SCIENCES,
BY TYPE, 2023–2030 (USD MILLION) 192
TABLE 101 US: CLINICAL ANALYTICS MARKET, BY OFFERING, 2023–2030 (USD MILLION) 193
TABLE 102 US: CLINICAL ANALYTICS MARKET, BY DATA SOURCE, 2023–2030 (USD MILLION) 194
TABLE 103 US: CLINICAL ANALYTICS MARKET, BY USE CASE, 2023–2030 (USD MILLION) 194
TABLE 104 US: CLINICAL ANALYTICS MARKET FOR HEALTHCARE USE CASES, BY TYPE,
2023–2030 (USD MILLION) 195
TABLE 105 US: CLINICAL ANALYTICS MARKET FOR LIFE SCIENCE USE CASES, BY TYPE,
2023–2030 (USD MILLION) 195
TABLE 106 US: CLINICAL ANALYTICS MARKET, BY END USER, 2023–2030 (USD MILLION) 196
TABLE 107 US: CLINICAL ANALYTICS MARKET FOR HEALTHCARE PROVIDERS, BY TYPE,
2023–2030 (USD MILLION) 196
TABLE 108 US: CLINICAL ANALYTICS MARKET FOR LIFE SCIENCES, BY TYPE,
2023–2030 (USD MILLION) 197
TABLE 109 CANADA: CLINICAL ANALYTICS MARKET, BY OFFERING, 2023–2030 (USD MILLION) 198
TABLE 110 CANADA: CLINICAL ANALYTICS MARKET, BY DATA SOURCE,
2023–2030 (USD MILLION) 198
TABLE 111 CANADA: CLINICAL ANALYTICS MARKET, BY USE CASE, 2023–2030 (USD MILLION) 199
TABLE 112 CANADA: CLINICAL ANALYTICS MARKET FOR HEALTHCARE USE CASES,
BY TYPE, 2023–2030 (USD MILLION) 199
TABLE 113 CANADA: CLINICAL ANALYTICS MARKET FOR LIFE SCIENCE USE CASES,
BY TYPE, 2023–2030 (USD MILLION) 200
TABLE 114 CANADA: CLINICAL ANALYTICS MARKET, BY END USER,
2023–2030 (USD MILLION) 200
TABLE 115 CANADA: CLINICAL ANALYTICS MARKET FOR HEALTHCARE PROVIDERS,
BY TYPE, 2023–2030 (USD MILLION) 201
TABLE 116 CANADA: CLINICAL ANALYTICS MARKET FOR LIFE SCIENCES, BY TYPE,
2023–2030 (USD MILLION) 201
TABLE 117 EUROPE: MACROECONOMIC OUTLOOK 203
TABLE 118 EUROPE: CLINICAL ANALYTICS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 203
TABLE 119 EUROPE: CLINICAL ANALYTICS MARKET, BY OFFERING,
2023–2030 (USD MILLION) 204
TABLE 120 EUROPE: CLINICAL ANALYTICS MARKET, BY DATA SOURCE,
2023–2030 (USD MILLION) 204
TABLE 121 EUROPE: CLINICAL ANALYTICS MARKET, BY USE CASE, 2023–2030 (USD MILLION) 205
TABLE 122 EUROPE: CLINICAL ANALYTICS MARKET FOR HEALTHCARE USE CASES,
BY TYPE, 2023–2030 (USD MILLION) 205
TABLE 123 EUROPE: CLINICAL ANALYTICS MARKET FOR LIFE SCIENCE USE CASES,
BY TYPE, 2023–2030 (USD MILLION) 206
TABLE 124 EUROPE: CLINICAL ANALYTICS MARKET, BY END USER,
2023–2030 (USD MILLION) 206
TABLE 125 EUROPE: CLINICAL ANALYTICS MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2023–2030 (USD MILLION) 207
TABLE 126 EUROPE: CLINICAL ANALYTICS MARKET FOR LIFE SCIENCES,
BY TYPE, 2023–2030 (USD MILLION) 207
TABLE 127 GERMANY: CLINICAL ANALYTICS MARKET, BY OFFERING,
2023–2030 (USD MILLION) 208
TABLE 128 GERMANY: CLINICAL ANALYTICS MARKET, BY DATA SOURCE,
2023–2030 (USD MILLION) 209
TABLE 129 GERMANY: CLINICAL ANALYTICS MARKET, BY USE CASE,
2023–2030 (USD MILLION) 209
TABLE 130 GERMANY: CLINICAL ANALYTICS MARKET FOR HEALTHCARE USE CASES,
BY TYPE, 2023–2030 (USD MILLION) 210
TABLE 131 GERMANY: CLINICAL ANALYTICS MARKET FOR LIFE SCIENCE USE CASES,
BY TYPE, 2023–2030 (USD MILLION) 210
TABLE 132 GERMANY: CLINICAL ANALYTICS MARKET, BY END USER,
2023–2030 (USD MILLION) 211
TABLE 133 GERMANY: CLINICAL ANALYTICS MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2023–2030 (USD MILLION) 211
TABLE 134 GERMANY: CLINICAL ANALYTICS MARKET FOR LIFE SCIENCES, BY TYPE,
2023–2030 (USD MILLION) 212
TABLE 135 FRANCE: CLINICAL ANALYTICS MARKET, BY OFFERING, 2023–2030 (USD MILLION) 213
TABLE 136 FRANCE: CLINICAL ANALYTICS MARKET, BY DATA SOURCE,
2023–2030 (USD MILLION) 213
TABLE 137 FRANCE: CLINICAL ANALYTICS MARKET, BY USE CASE, 2023–2030 (USD MILLION) 214
TABLE 138 FRANCE: CLINICAL ANALYTICS MARKET FOR HEALTHCARE USE CASES,
BY TYPE, 2023–2030 (USD MILLION) 214
TABLE 139 FRANCE: CLINICAL ANALYTICS MARKET FOR LIFE SCIENCE USE CASES,
BY TYPE, 2023–2030 (USD MILLION) 215
TABLE 140 FRANCE: CLINICAL ANALYTICS MARKET, BY END USER,
2023–2030 (USD MILLION) 215
TABLE 141 FRANCE: CLINICAL ANALYTICS MARKET FOR HEALTHCARE PROVIDERS,
BY TYPE, 2023–2030 (USD MILLION) 216
TABLE 142 FRANCE: CLINICAL ANALYTICS MARKET FOR LIFE SCIENCES, BY TYPE,
2023–2030 (USD MILLION) 216
TABLE 143 UK: CLINICAL ANALYTICS MARKET, BY OFFERING, 2023–2030 (USD MILLION) 217
TABLE 144 UK: CLINICAL ANALYTICS MARKET, BY DATA SOURCE, 2023–2030 (USD MILLION) 218
TABLE 145 UK: CLINICAL ANALYTICS MARKET, BY USE CASE, 2023–2030 (USD MILLION) 218
TABLE 146 UK: CLINICAL ANALYTICS MARKET FOR HEALTHCARE USE CASES, BY TYPE,
2023–2030 (USD MILLION) 219
TABLE 147 UK: CLINICAL ANALYTICS MARKET FOR LIFE SCIENCE USE CASES, BY TYPE,
2023–2030 (USD MILLION) 219
TABLE 148 UK: CLINICAL ANALYTICS MARKET, BY END USER, 2023–2030 (USD MILLION) 220
TABLE 149 UK: CLINICAL ANALYTICS MARKET FOR HEALTHCARE PROVIDERS, BY TYPE,
2023–2030 (USD MILLION) 220
TABLE 150 UK: CLINICAL ANALYTICS MARKET FOR LIFE SCIENCES, BY TYPE,
2023–2030 (USD MILLION) 221
TABLE 151 ITALY: CLINICAL ANALYTICS MARKET, BY OFFERING, 2023–2030 (USD MILLION) 222
TABLE 152 ITALY: CLINICAL ANALYTICS MARKET, BY DATA SOURCE,
2023–2030 (USD MILLION) 222
TABLE 153 ITALY: CLINICAL ANALYTICS MARKET, BY USE CASE, 2023–2030 (USD MILLION) 223
TABLE 154 ITALY: CLINICAL ANALYTICS MARKET FOR HEALTHCARE USE CASES, BY TYPE, 2023–2030 (USD MILLION) 223
TABLE 155 ITALY: CLINICAL ANALYTICS MARKET FOR LIFE SCIENCE USE CASES, BY TYPE, 2023–2030 (USD MILLION) 224
TABLE 156 ITALY: CLINICAL ANALYTICS MARKET, BY END USER, 2023–2030 (USD MILLION) 224
TABLE 157 ITALY: CLINICAL ANALYTICS MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2023–2030 (USD MILLION) 225
TABLE 158 ITALY: CLINICAL ANALYTICS MARKET FOR LIFE SCIENCES, BY TYPE,
2023–2030 (USD MILLION) 225
TABLE 159 SPAIN: CLINICAL ANALYTICS MARKET, BY OFFERING, 2023–2030 (USD MILLION) 226
TABLE 160 SPAIN: CLINICAL ANALYTICS MARKET, BY DATA SOURCE,
2023–2030 (USD MILLION) 227
TABLE 161 SPAIN: CLINICAL ANALYTICS MARKET, BY USE CASE, 2023–2030 (USD MILLION) 227
TABLE 162 SPAIN: CLINICAL ANALYTICS MARKET FOR HEALTHCARE USE CASES, BY TYPE, 2023–2030 (USD MILLION) 228
TABLE 163 SPAIN: CLINICAL ANALYTICS MARKET FOR LIFE SCIENCE USE CASES, BY TYPE, 2023–2030 (USD MILLION) 228
TABLE 164 SPAIN: CLINICAL ANALYTICS MARKET, BY END USER, 2023–2030 (USD MILLION) 229
TABLE 165 SPAIN: CLINICAL ANALYTICS MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2023–2030 (USD MILLION) 229
TABLE 166 SPAIN: CLINICAL ANALYTICS MARKET FOR LIFE SCIENCES, BY TYPE,
2023–2030 (USD MILLION) 230
TABLE 167 REST OF EUROPE: CLINICAL ANALYTICS MARKET, BY OFFERING,
2023–2030 (USD MILLION) 231
TABLE 168 REST OF EUROPE: CLINICAL ANALYTICS MARKET, BY DATA SOURCE,
2023–2030 (USD MILLION) 231
TABLE 169 REST OF EUROPE: CLINICAL ANALYTICS MARKET, BY USE CASE,
2023–2030 (USD MILLION) 232
TABLE 170 REST OF EUROPE: CLINICAL ANALYTICS MARKET FOR HEALTHCARE USE CASES,
BY TYPE, 2023–2030 (USD MILLION) 232
TABLE 171 REST OF EUROPE: CLINICAL ANALYTICS MARKET FOR LIFE SCIENCE USE CASES, BY TYPE, 2023–2030 (USD MILLION) 233
TABLE 172 REST OF EUROPE: CLINICAL ANALYTICS MARKET, BY END USER,
2023–2030 (USD MILLION) 233
TABLE 173 REST OF EUROPE: CLINICAL ANALYTICS MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2023–2030 (USD MILLION) 234
TABLE 174 REST OF EUROPE: CLINICAL ANALYTICS MARKET FOR LIFE SCIENCES,
BY TYPE, 2023–2030 (USD MILLION) 234
TABLE 175 ASIA PACIFIC: MACROECONOMIC OUTLOOK 236
TABLE 176 ASIA PACIFIC: CLINICAL ANALYTICS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 237
TABLE 177 ASIA PACIFIC: CLINICAL ANALYTICS MARKET, BY OFFERING,
2023–2030 (USD MILLION) 238
TABLE 178 ASIA PACIFIC: CLINICAL ANALYTICS MARKET, BY DATA SOURCE,
2023–2030 (USD MILLION) 238
TABLE 179 ASIA PACIFIC: CLINICAL ANALYTICS MARKET, BY USE CASE,
2023–2030 (USD MILLION) 239
TABLE 180 ASIA PACIFIC: CLINICAL ANALYTICS MARKET FOR HEALTHCARE USE CASES,
BY TYPE, 2023–2030 (USD MILLION) 239
TABLE 181 ASIA PACIFIC: CLINICAL ANALYTICS MARKET FOR LIFE SCIENCE USE CASES,
BY TYPE, 2023–2030 (USD MILLION) 240
TABLE 182 ASIA PACIFIC: CLINICAL ANALYTICS MARKET, BY END USER,
2023–2030 (USD MILLION) 240
TABLE 183 ASIA PACIFIC: CLINICAL ANALYTICS MARKET FOR HEALTHCARE PROVIDERS,
BY TYPE, 2023–2030 (USD MILLION) 241
TABLE 184 ASIA PACIFIC: CLINICAL ANALYTICS MARKET FOR LIFE SCIENCES, BY TYPE,
2023–2030 (USD MILLION) 241
TABLE 185 CHINA: CLINICAL ANALYTICS MARKET, BY OFFERING, 2023–2030 (USD MILLION) 243
TABLE 186 CHINA: CLINICAL ANALYTICS MARKET, BY DATA SOURCE,
2023–2030 (USD MILLION) 243
TABLE 187 CHINA: CLINICAL ANALYTICS MARKET, BY USE CASE, 2023–2030 (USD MILLION) 244
TABLE 188 CHINA: CLINICAL ANALYTICS MARKET FOR HEALTHCARE USE CASES,
BY TYPE, 2023–2030 (USD MILLION) 244
TABLE 189 CHINA: CLINICAL ANALYTICS MARKET FOR LIFE SCIENCE USE CASES,
BY TYPE, 2023–2030 (USD MILLION) 245
TABLE 190 CHINA: CLINICAL ANALYTICS MARKET, BY END USER, 2023–2030 (USD MILLION) 245
TABLE 191 CHINA: CLINICAL ANALYTICS MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2023–2030 (USD MILLION) 246
TABLE 192 CHINA: CLINICAL ANALYTICS MARKET FOR LIFE SCIENCES, BY TYPE,
2023–2030 (USD MILLION) 246
TABLE 193 JAPAN: CLINICAL ANALYTICS MARKET, BY OFFERING, 2023–2030 (USD MILLION) 248
TABLE 194 JAPAN: CLINICAL ANALYTICS MARKET, BY DATA SOURCE,
2023–2030 (USD MILLION) 248
TABLE 195 JAPAN: CLINICAL ANALYTICS MARKET, BY USE CASE, 2023–2030 (USD MILLION) 249
TABLE 196 JAPAN: CLINICAL ANALYTICS MARKET FOR HEALTHCARE USE CASES,
BY TYPE, 2023–2030 (USD MILLION) 249
TABLE 197 JAPAN: CLINICAL ANALYTICS MARKET FOR LIFE SCIENCE USE CASES,
BY TYPE, 2023–2030 (USD MILLION) 250
TABLE 198 JAPAN: CLINICAL ANALYTICS MARKET, BY END USER, 2023–2030 (USD MILLION) 250
TABLE 199 JAPAN: CLINICAL ANALYTICS MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2023–2030 (USD MILLION) 251
TABLE 200 JAPAN: CLINICAL ANALYTICS MARKET FOR LIFE SCIENCES, BY TYPE,
2023–2030 (USD MILLION) 251
TABLE 201 INDIA: CLINICAL ANALYTICS MARKET, BY OFFERING, 2023–2030 (USD MILLION) 252
TABLE 202 INDIA: CLINICAL ANALYTICS MARKET, BY DATA SOURCE,
2023–2030 (USD MILLION) 253
TABLE 203 INDIA: CLINICAL ANALYTICS MARKET, BY USE CASE, 2023–2030 (USD MILLION) 253
TABLE 204 INDIA: CLINICAL ANALYTICS MARKET FOR HEALTHCARE USE CASES, BY TYPE, 2023–2030 (USD MILLION) 254
TABLE 205 INDIA: CLINICAL ANALYTICS MARKET FOR LIFE SCIENCE USE CASES, BY TYPE, 2023–2030 (USD MILLION) 254
TABLE 206 INDIA: CLINICAL ANALYTICS MARKET, BY END USER, 2023–2030 (USD MILLION) 255
TABLE 207 INDIA: CLINICAL ANALYTICS MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2023–2030 (USD MILLION) 255
TABLE 208 INDIA: CLINICAL ANALYTICS MARKET FOR LIFE SCIENCES, BY TYPE,
2023–2030 (USD MILLION) 256
TABLE 209 SOUTH KOREA: CLINICAL ANALYTICS MARKET, BY OFFERING,
2023–2030 (USD MILLION) 257
TABLE 210 SOUTH KOREA: CLINICAL ANALYTICS MARKET, BY DATA SOURCE,
2023–2030 (USD MILLION) 258
TABLE 211 SOUTH KOREA: CLINICAL ANALYTICS MARKET, BY USE CASE,
2023–2030 (USD MILLION) 258
TABLE 212 SOUTH KOREA: CLINICAL ANALYTICS MARKET FOR HEALTHCARE USE CASES,
BY TYPE, 2023–2030 (USD MILLION) 259
TABLE 213 SOUTH KOREA: CLINICAL ANALYTICS MARKET FOR LIFE SCIENCE USE CASES,
BY TYPE, 2023–2030 (USD MILLION) 259
TABLE 214 SOUTH KOREA: CLINICAL ANALYTICS MARKET, BY END USER,
2023–2030 (USD MILLION) 260
TABLE 215 SOUTH KOREA: CLINICAL ANALYTICS MARKET FOR HEALTHCARE PROVIDERS,
BY TYPE, 2023–2030 (USD MILLION) 260
TABLE 216 SOUTH KOREA: CLINICAL ANALYTICS MARKET FOR LIFE SCIENCES,
BY TYPE, 2023–2030 (USD MILLION) 261
TABLE 217 REST OF ASIA PACIFIC: CLINICAL ANALYTICS MARKET, BY OFFERING,
2023–2030 (USD MILLION) 262
TABLE 218 REST OF ASIA PACIFIC: CLINICAL ANALYTICS MARKET, BY DATA SOURCE,
2023–2030 (USD MILLION) 262
TABLE 219 REST OF ASIA PACIFIC: CLINICAL ANALYTICS MARKET, BY USE CASE,
2023–2030 (USD MILLION) 263
TABLE 220 REST OF ASIA PACIFIC: CLINICAL ANALYTICS MARKET FOR HEALTHCARE USE CASES, BY TYPE, 2023–2030 (USD MILLION) 263
TABLE 221 REST OF ASIA PACIFIC: CLINICAL ANALYTICS MARKET FOR LIFE SCIENCE USE CASES, BY TYPE, 2023–2030 (USD MILLION) 264
TABLE 222 REST OF ASIA PACIFIC: CLINICAL ANALYTICS MARKET, BY END USER,
2023–2030 (USD MILLION) 264
TABLE 223 REST OF ASIA PACIFIC: CLINICAL ANALYTICS MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2023–2030 (USD MILLION) 265
TABLE 224 REST OF ASIA PACIFIC: CLINICAL ANALYTICS MARKET FOR LIFE SCIENCES,
BY TYPE, 2023–2030 (USD MILLION) 265
TABLE 225 LATIN AMERICA: MACROECONOMIC OUTLOOK 267
TABLE 226 LATIN AMERICA: CLINICAL ANALYTICS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 267
TABLE 227 LATIN AMERICA: CLINICAL ANALYTICS MARKET, BY OFFERING,
2023–2030 (USD MILLION) 268
TABLE 228 LATIN AMERICA: CLINICAL ANALYTICS MARKET, BY DATA SOURCE,
2023–2030 (USD MILLION) 268
TABLE 229 LATIN AMERICA: CLINICAL ANALYTICS MARKET, BY USE CASE,
2023–2030 (USD MILLION) 269
TABLE 230 LATIN AMERICA: CLINICAL ANALYTICS MARKET FOR HEALTHCARE USE CASES,
BY TYPE, 2023–2030 (USD MILLION) 269
TABLE 231 LATIN AMERICA: CLINICAL ANALYTICS MARKET FOR LIFE SCIENCE USE CASES,
BY TYPE, 2023–2030 (USD MILLION) 270
TABLE 232 LATIN AMERICA: CLINICAL ANALYTICS MARKET, BY END USER,
2023–2030 (USD MILLION) 270
TABLE 233 LATIN AMERICA: CLINICAL ANALYTICS MARKET FOR HEALTHCARE
PROVIDERS, BY TYPE, 2023–2030 (USD MILLION) 271
TABLE 234 LATIN AMERICA: CLINICAL ANALYTICS MARKET FOR LIFE SCIENCES,
BY TYPE, 2023–2030 (USD MILLION) 271
TABLE 235 BRAZIL: CLINICAL ANALYTICS MARKET, BY OFFERING, 2023–2030 (USD MILLION) 272
TABLE 236 BRAZIL: CLINICAL ANALYTICS MARKET, BY DATA SOURCE,
2023–2030 (USD MILLION) 273
TABLE 237 BRAZIL: CLINICAL ANALYTICS MARKET, BY USE CASE, 2023–2030 (USD MILLION) 273
TABLE 238 BRAZIL: CLINICAL ANALYTICS MARKET FOR HEALTHCARE USE CASES,
BY TYPE, 2023–2030 (USD MILLION) 274
TABLE 239 BRAZIL: CLINICAL ANALYTICS MARKET FOR LIFE SCIENCE USE CASES,
BY TYPE, 2023–2030 (USD MILLION) 274
TABLE 240 BRAZIL: CLINICAL ANALYTICS MARKET, BY END USER, 2023–2030 (USD MILLION) 275
TABLE 241 BRAZIL: CLINICAL ANALYTICS MARKET FOR HEALTHCARE PROVIDERS,
BY TYPE, 2023–2030 (USD MILLION) 275
TABLE 242 BRAZIL: CLINICAL ANALYTICS MARKET FOR LIFE SCIENCES, BY TYPE,
2023–2030 (USD MILLION) 276
TABLE 243 MEXICO: CLINICAL ANALYTICS MARKET, BY OFFERING, 2023–2030 (USD MILLION) 277
TABLE 244 MEXICO: CLINICAL ANALYTICS MARKET, BY DATA SOURCE,
2023–2030 (USD MILLION) 277
TABLE 245 MEXICO: CLINICAL ANALYTICS MARKET, BY USE CASE, 2023–2030 (USD MILLION) 278
TABLE 246 MEXICO: CLINICAL ANALYTICS MARKET FOR HEALTHCARE USE CASES, BY TYPE, 2023–2030 (USD MILLION) 278
TABLE 247 MEXICO: CLINICAL ANALYTICS MARKET FOR LIFE SCIENCE USE CASES, BY TYPE, 2023–2030 (USD MILLION) 279
TABLE 248 MEXICO: CLINICAL ANALYTICS MARKET, BY END USER, 2023–2030 (USD MILLION) 279
TABLE 249 MEXICO: CLINICAL ANALYTICS MARKET FOR HEALTHCARE PROVIDERS,
BY TYPE, 2023–2030 (USD MILLION) 280
TABLE 250 MEXICO: CLINICAL ANALYTICS MARKET FOR LIFE SCIENCES, BY TYPE,
2023–2030 (USD MILLION) 280
TABLE 251 REST OF LATIN AMERICA: CLINICAL ANALYTICS MARKET, BY OFFERING,
2023–2030 (USD MILLION) 281
TABLE 252 REST OF LATIN AMERICA: CLINICAL ANALYTICS MARKET, BY DATA SOURCE,
2023–2030 (USD MILLION) 282
TABLE 253 REST OF LATIN AMERICA: CLINICAL ANALYTICS MARKET, BY USE CASE,
2023–2030 (USD MILLION) 282
TABLE 254 REST OF LATIN AMERICA: CLINICAL ANALYTICS MARKET FOR
HEALTHCARE USE CASES, BY TYPE, 2023–2030 (USD MILLION) 283
TABLE 255 REST OF LATIN AMERICA: CLINICAL ANALYTICS MARKET FOR
LIFE SCIENCE USE CASES, BY TYPE, 2023–2030 (USD MILLION) 283
TABLE 256 REST OF LATIN AMERICA: CLINICAL ANALYTICS MARKET, BY END USER,
2023–2030 (USD MILLION) 284
TABLE 257 REST OF LATIN AMERICA: CLINICAL ANALYTICS MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2023–2030 (USD MILLION) 284
TABLE 258 REST OF LATIN AMERICA: CLINICAL ANALYTICS MARKET FOR LIFE SCIENCES,
BY TYPE, 2023–2030 (USD MILLION) 285
TABLE 259 MIDDLE EAST & AFRICA: MACROECONOMIC OUTLOOK 286
TABLE 260 MIDDLE EAST & AFRICA: CLINICAL ANALYTICS MARKET, BY REGION,
2023–2030 (USD MILLION) 287
TABLE 261 MIDDLE EAST & AFRICA: CLINICAL ANALYTICS MARKET, BY OFFERING,
2023–2030 (USD MILLION) 287
TABLE 262 MIDDLE EAST & AFRICA: CLINICAL ANALYTICS MARKET, BY DATA SOURCE,
2023–2030 (USD MILLION) 288
TABLE 263 MIDDLE EAST & AFRICA: CLINICAL ANALYTICS MARKET, BY USE CASE,
2023–2030 (USD MILLION) 288
TABLE 264 MIDDLE EAST & AFRICA: CLINICAL ANALYTICS MARKET FOR HEALTHCARE USE CASES, BY TYPE, 2023–2030 (USD MILLION) 289
TABLE 265 MIDDLE EAST & AFRICA: CLINICAL ANALYTICS MARKET FOR LIFE SCIENCE USE CASES, BY TYPE, 2023–2030 (USD MILLION) 289
TABLE 266 MIDDLE EAST & AFRICA: CLINICAL ANALYTICS MARKET, BY END USER,
2023–2030 (USD MILLION) 290
TABLE 267 MIDDLE EAST & AFRICA: CLINICAL ANALYTICS MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2023–2030 (USD MILLION) 290
TABLE 268 MIDDLE EAST & AFRICA: CLINICAL ANALYTICS MARKET FOR LIFE SCIENCES,
BY TYPE, 2023–2030 (USD MILLION) 291
TABLE 269 GCC COUNTRIES: CLINICAL ANALYTICS MARKET, BY OFFERING,
2023–2030 (USD MILLION) 292
TABLE 270 GCC COUNTRIES: CLINICAL ANALYTICS MARKET, BY DATA SOURCE,
2023–2030 (USD MILLION) 292
TABLE 271 GCC COUNTRIES: CLINICAL ANALYTICS MARKET, BY USE CASE,
2023–2030 (USD MILLION) 293
TABLE 272 GCC COUNTRIES: CLINICAL ANALYTICS MARKET FOR HEALTHCARE USE CASES,
BY TYPE, 2023–2030 (USD MILLION) 293
TABLE 273 GCC COUNTRIES: CLINICAL ANALYTICS MARKET FOR LIFE SCIENCE USE CASES,
BY TYPE, 2023–2030 (USD MILLION) 294
TABLE 274 GCC COUNTRIES: CLINICAL ANALYTICS MARKET, BY END USER,
2023–2030 (USD MILLION) 294
TABLE 275 GCC COUNTRIES: CLINICAL ANALYTICS MARKET FOR HEALTHCARE PROVIDERS,
BY TYPE, 2023–2030 (USD MILLION) 295
TABLE 276 GCC COUNTRIES: CLINICAL ANALYTICS MARKET FOR LIFE SCIENCES, BY TYPE, 2023–2030 (USD MILLION) 295
TABLE 277 SAUDI ARABIA: CLINICAL ANALYTICS MARKET, BY OFFERING,
2023–2030 (USD MILLION) 296
TABLE 278 SAUDI ARABIA: CLINICAL ANALYTICS MARKET, BY DATA SOURCE,
2023–2030 (USD MILLION) 297
TABLE 279 SAUDI ARABIA: CLINICAL ANALYTICS MARKET, BY USE CASE,
2023–2030 (USD MILLION) 297
TABLE 280 SAUDI ARABIA: CLINICAL ANALYTICS MARKET FOR HEALTHCARE USE CASES,
BY TYPE, 2023–2030 (USD MILLION) 298
TABLE 281 SAUDI ARABIA: CLINICAL ANALYTICS MARKET FOR LIFE SCIENCE USE CASES,
BY TYPE, 2023–2030 (USD MILLION) 298
TABLE 282 SAUDI ARABIA: CLINICAL ANALYTICS MARKET, BY END USER,
2023–2030 (USD MILLION) 299
TABLE 283 SAUDI ARABIA: CLINICAL ANALYTICS MARKET FOR HEALTHCARE PROVIDERS,
BY TYPE, 2023–2030 (USD MILLION) 299
TABLE 284 SAUDI ARABIA: CLINICAL ANALYTICS MARKET FOR LIFE SCIENCES, BY TYPE,
2023–2030 (USD MILLION) 300
TABLE 285 UAE: CLINICAL ANALYTICS MARKET, BY OFFERING, 2023–2030 (USD MILLION) 301
TABLE 286 UAE: CLINICAL ANALYTICS MARKET, BY DATA SOURCE, 2023–2030 (USD MILLION) 301
TABLE 287 UAE: CLINICAL ANALYTICS MARKET, BY USE CASE, 2023–2030 (USD MILLION) 302
TABLE 288 UAE: CLINICAL ANALYTICS MARKET FOR HEALTHCARE USE CASES, BY TYPE,
2023–2030 (USD MILLION) 302
TABLE 289 UAE: CLINICAL ANALYTICS MARKET FOR LIFE SCIENCE USE CASES, BY TYPE, 2023–2030 (USD MILLION) 303
TABLE 290 UAE: CLINICAL ANALYTICS MARKET, BY END USER, 2023–2030 (USD MILLION) 303
TABLE 291 UAE: CLINICAL ANALYTICS MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2023–2030 (USD MILLION) 304
TABLE 292 UAE: CLINICAL ANALYTICS MARKET FOR LIFE SCIENCES, BY TYPE,
2023–2030 (USD MILLION) 304
TABLE 293 REST OF GCC COUNTRIES: CLINICAL ANALYTICS MARKET, BY OFFERING,
2023–2030 (USD MILLION) 305
TABLE 294 REST OF GCC COUNTRIES: CLINICAL ANALYTICS MARKET, BY DATA SOURCE, 2023–2030 (USD MILLION) 306
TABLE 295 REST OF GCC COUNTRIES: CLINICAL ANALYTICS MARKET, BY USE CASE,
2023–2030 (USD MILLION) 306
TABLE 296 REST OF GCC COUNTRIES: CLINICAL ANALYTICS MARKET FOR HEALTHCARE USE CASES, BY TYPE, 2023–2030 (USD MILLION) 307
TABLE 297 REST OF GCC COUNTRIES: CLINICAL ANALYTICS MARKET FOR LIFE SCIENCE USE CASES, BY TYPE, 2023–2030 (USD MILLION) 307
TABLE 298 REST OF GCC COUNTRIES: CLINICAL ANALYTICS MARKET, BY END USER,
2023–2030 (USD MILLION) 308
TABLE 299 REST OF GCC COUNTRIES: CLINICAL ANALYTICS MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2023–2030 (USD MILLION) 308
TABLE 300 REST OF GCC COUNTRIES: CLINICAL ANALYTICS MARKET FOR LIFE SCIENCES,
BY TYPE, 2023–2030 (USD MILLION) 309
TABLE 301 SOUTH AFRICA: CLINICAL ANALYTICS MARKET, BY OFFERING,
2023–2030 (USD MILLION) 310
TABLE 302 SOUTH AFRICA: CLINICAL ANALYTICS MARKET, BY DATA SOURCE,
2023–2030 (USD MILLION) 310
TABLE 303 SOUTH AFRICA: CLINICAL ANALYTICS MARKET, BY USE CASE,
2023–2030 (USD MILLION) 311
TABLE 304 SOUTH AFRICA: CLINICAL ANALYTICS MARKET FOR HEALTHCARE USE CASES,
BY TYPE, 2023–2030 (USD MILLION) 311
TABLE 305 SOUTH AFRICA: CLINICAL ANALYTICS MARKET FOR LIFE SCIENCE USE CASES,
BY TYPE, 2023–2030 (USD MILLION) 312
TABLE 306 SOUTH AFRICA: CLINICAL ANALYTICS MARKET, BY END USER,
2023–2030 (USD MILLION) 312
TABLE 307 SOUTH AFRICA: CLINICAL ANALYTICS MARKET FOR HEALTHCARE PROVIDERS,
BY TYPE, 2023–2030 (USD MILLION) 313
TABLE 308 SOUTH AFRICA: CLINICAL ANALYTICS MARKET FOR LIFE SCIENCES, BY TYPE, 2023–2030 (USD MILLION) 313
TABLE 309 REST OF MIDDLE EAST & AFRICA: CLINICAL ANALYTICS MARKET, BY OFFERING, 2023–2030 (USD MILLION) 314
TABLE 310 REST OF MIDDLE EAST & AFRICA: CLINICAL ANALYTICS MARKET, BY DATA SOURCE, 2023–2030 (USD MILLION) 315
TABLE 311 REST OF MIDDLE EAST & AFRICA: CLINICAL ANALYTICS MARKET,
BY USE CASE, 2023–2030 (USD MILLION) 315
TABLE 312 REST OF MIDDLE EAST & AFRICA: CLINICAL ANALYTICS MARKET FOR HEALTHCARE USE CASES, BY TYPE, 2023–2030 (USD MILLION) 316
TABLE 313 REST OF MIDDLE EAST & AFRICA: CLINICAL ANALYTICS MARKET FOR LIFE SCIENCE USE CASES, BY TYPE, 2023–2030 (USD MILLION) 316
TABLE 314 REST OF MIDDLE EAST & AFRICA: CLINICAL ANALYTICS MARKET, BY END USER, 2023–2030 (USD MILLION) 317
TABLE 315 REST OF MIDDLE EAST & AFRICA: CLINICAL ANALYTICS MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2023–2030 (USD MILLION) 317
TABLE 316 REST OF MIDDLE EAST AND AFRICA: CLINICAL ANALYTICS MARKET FOR LIFE SCIENCES, BY TYPE, 2023–2030 (USD MILLION) 318
TABLE 317 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN CLINICAL ANALYTICS MARKET, JANUARY 2022–OCTOBER 2025 320
TABLE 318 CLINICAL ANALYTICS MARKET: DEGREE OF COMPETITION 325
TABLE 319 CLINICAL ANALYTICS MARKET: COMPANY FOOTPRINT 332
TABLE 320 CLINICAL ANALYTICS MARKET: REGION FOOTPRINT 333
TABLE 321 CLINICAL ANALYTICS MARKET: OFFERING FOOTPRINT 334
TABLE 322 CLINICAL ANALYTICS MARKET: DATA SOURCE FOOTPRINT 335
TABLE 323 CLINICAL ANALYTICS MARKET: USE CASE FOOTPRINT 336
TABLE 324 CLINICAL ANALYTICS MARKET: END-USER FOOTPRINT 337
TABLE 325 CLINICAL ANALYTICS MARKET: DETAILED LIST OF KEY STARTUPS/SMES 340
TABLE 326 CLINICAL ANALYTICS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES 340
TABLE 327 CLINICAL ANALYTICS MARKET: PRODUCT LAUNCHES AND APPROVALS,
JANUARY 2022–OCTOBER 2025 341
TABLE 328 CLINICAL ANALYTICS MARKET: DEALS, JANUARY 2022–OCTOBER 2025 342
TABLE 329 CLINICAL ANALYTICS MARKET: OTHER DEVELOPMENTS,
JANUARY 2022–OCTOBER 2025 343
TABLE 330 IQVIA: COMPANY OVERVIEW 345
TABLE 331 IQVIA: PRODUCTS OFFERED 346
TABLE 332 IQVIA: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–OCTOBER 2025 347
TABLE 333 IQVIA: DEALS, JANUARY 2022–OCTOBER 2025 349
TABLE 334 OPTUM, INC.: COMPANY OVERVIEW 352
TABLE 335 OPTUM, INC.: PRODUCTS OFFERED 353
TABLE 336 OPTUM, INC.: PRODUCT LAUNCHES AND APPROVALS,
JANUARY 2022–OCTOBER 2025 355
TABLE 337 OPTUM, INC.: DEALS, JANUARY 2022–OCTOBER 2025 356
TABLE 338 MERATIVE: COMPANY OVERVIEW 358
TABLE 339 MERATIVE: PRODUCTS OFFERED 359
TABLE 340 MERATIVE: DEALS, JANUARY 2022–OCTOBER 2025 360
TABLE 341 EPIC SYSTEMS CORPORATION: COMPANY OVERVIEW 362
TABLE 342 EPIC SYSTEMS CORPORATION: PRODUCTS OFFERED 363
TABLE 343 EPIC SYSTEMS CORPORATION: PRODUCT LAUNCHES AND APPROVALS,
JANUARY 2022–OCTOBER 2025 364
TABLE 344 EPIC SYSTEMS CORPORATION: DEALS, JANUARY 2022–OCTOBER 2025 365
TABLE 345 GE HEALTHCARE: COMPANY OVERVIEW 368
TABLE 346 GE HEALTHCARE: PRODUCTS OFFERED 370
TABLE 347 GE HEALTHCARE: PRODUCT LAUNCHES AND APPROVALS,
JANUARY 2022–OCTOBER 2025 371
TABLE 348 GE HEALTHCARE: DEALS, JANUARY 2022–OCTOBER 2025 372
TABLE 349 GE HEALTHCARE: OTHER DEVELOPMENTS, JANUARY 2022–OCTOBER 2025 373
TABLE 350 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW 375
TABLE 351 SIEMENS HEALTHINEERS AG: PRODUCTS OFFERED 377
TABLE 352 SIEMENS HEALTHINEERS AG: PRODUCT LAUNCHES AND APPROVALS,
JANUARY 2022–OCTOBER 2025 378
TABLE 353 SIEMENS HEALTHINEERS AG: DEALS, JANUARY 2022–OCTOBER 2025 379
TABLE 354 SIEMENS HEALTHINEERS AG: OTHER DEVELOPMENTS,
JANUARY 2022–OCTOBER 2025 381
TABLE 355 ORACLE: COMPANY OVERVIEW 383
TABLE 356 ORACLE: PRODUCTS OFFERED 385
TABLE 357 ORACLE: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–OCTOBER 2025 387
TABLE 358 ORACLE: DEALS, JANUARY 2022–OCTOBER 2025 388
TABLE 359 MCKESSON CORPORATION: COMPANY OVERVIEW 390
TABLE 360 MCKESSON CORPORATION: PRODUCTS OFFERED 391
TABLE 361 MCKESSON CORPORATION: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–OCTOBER 2025 393
TABLE 362 MCKESSON CORPORATION: DEALS, JANUARY 2022–OCTOBER 2025 394
TABLE 363 MCKESSON CORPORATION: OTHER DEVELOPMENTS,
JANUARY 2022–OCTOBER 2025 395
TABLE 364 VERADIGM LLC: COMPANY OVERVIEW 396
TABLE 365 VERADIGM LLC: PRODUCTS OFFERED 398
TABLE 366 VERADIGM LLC: PRODUCT LAUNCHES AND APPROVALS,
JANUARY 2022–OCTOBER 2025 399
TABLE 367 VERADIGM LLC: DEALS, JANUARY 2022–OCTOBER 2025 401
TABLE 368 VERADIGM LLC: OTHER DEVELOPMENTS, JANUARY 2022–OCTOBER 2025 402
TABLE 369 INOVALON: COMPANY OVERVIEW 403
TABLE 370 INOVALON: PRODUCTS OFFERED 404
TABLE 371 INOVALON: PRODUCT LAUNCHES AND APPROVALS,
JANUARY 2022–OCTOBER 2025 405
TABLE 372 INOVALON: DEALS, JANUARY 2022–OCTOBER 2025 406
TABLE 373 WNS (HOLDINGS) LTD.: COMPANY OVERVIEW 407
TABLE 374 WNS (HOLDINGS) LTD.: PRODUCTS OFFERED 409
TABLE 375 WNS (HOLDINGS) LTD.: DEALS, JANUARY 2022–OCTOBER 2025 410
TABLE 376 WNS (HOLDINGS) LTD.: OTHER DEVELOPMENTS, JANUARY 2022–OCTOBER 2025 411
TABLE 377 SOPHIA GENETICS: COMPANY OVERVIEW 412
TABLE 378 SOPHIA GENETICS: PRODUCTS OFFERED 413
TABLE 379 SOPHIA GENETICS: PRODUCT LAUNCHES AND APPROVALS,
JANUARY 2022–OCTOBER 2025 414
TABLE 380 SOPHIA GENETICS: DEALS, JANUARY 2022–OCTOBER 2025 415
TABLE 381 COTIVITI, INC.: COMPANY OVERVIEW 416
TABLE 382 COTIVITI, INC.: PRODUCTS OFFERED 417
TABLE 383 COTIVITI, INC.: PRODUCT LAUNCHES AND APPROVALS,
JANUARY 2022–OCTOBER 2025 418
TABLE 384 COTIVITI, INC.: DEALS, JANUARY 2022–OCTOBER 2025 419
TABLE 385 HEALTH CATALYST: COMPANY OVERVIEW 420
TABLE 386 HEALTH CATALYST: PRODUCTS OFFERED 421
TABLE 387 HEALTH CATALYST: PRODUCT LAUNCHES AND APPROVALS,
JANUARY 2022–OCTOBER 2025 423
TABLE 388 HEALTH CATALYST: DEALS, JANUARY 2022–OCTOBER 2025 424
TABLE 389 COGNIZANT: COMPANY OVERVIEW 425
TABLE 390 COGNIZANT: PRODUCTS OFFERED 427
TABLE 391 COGNIZANT: PRODUCT LAUNCHES AND APPROVALS,
JANUARY 2022–OCTOBER 2025 428
TABLE 392 COGNIZANT: DEALS, JANUARY 2022–OCTOBER 2025 429
TABLE 393 F. HOFFMANN-LA ROCHE LTD: COMPANY OVERVIEW 430
TABLE 394 F. HOFFMANN-LA ROCHE LTD: PRODUCTS OFFERED 432
TABLE 395 F. HOFFMANN-LA ROCHE LTD: PRODUCT LAUNCHES AND APPROVALS,
JANUARY 2022–OCTOBER 2025 433
TABLE 396 F. HOFFMANN-LA ROCHE LTD: DEALS, JANUARY 2022–OCTOBER 2025 434
TABLE 397 KONINKLIJKE PHILIPS N.V.: COMPANY OVERVIEW 436
TABLE 398 KONINKLIJKE PHILIPS N.V.: PRODUCTS OFFERED 438
TABLE 399 KONINKLIJKE PHILIPS N.V.: PRODUCT LAUNCHES AND APPROVALS,
JANUARY 2022–OCTOBER 2025 439
TABLE 400 KONINKLIJKE PHILIPS N.V.: DEALS, JANUARY 2022–OCTOBER 2025 440
TABLE 401 DASSAULT SYSTÈMES: COMPANY OVERVIEW 441
TABLE 402 DASSAULT SYSTÈMES: PRODUCTS OFFERED 443
TABLE 403 DASSAULT SYSTÈMES: PRODUCT LAUNCHES AND APPROVALS,
JANUARY 2022–OCTOBER 2025 444
TABLE 404 DASSAULT SYSTÈMES: DEALS, JANUARY 2022–OCTOBER 2025 446
TABLE 405 ATHENAHEALTH, INC.: COMPANY OVERVIEW 451
TABLE 406 ATHENAHEALTH, INC.: PRODUCTS OFFERED 452
TABLE 407 ATHENAHEALTH, INC.: PRODUCT LAUNCHES AND APPROVALS,
JANUARY 2022–OCTOBER 2025 453
TABLE 408 ATHENAHEALTH, INC.: DEALS, JANUARY 2022–OCTOBER 2025 454
TABLE 409 VEEVA SYSTEMS: COMPANY OVERVIEW 455
TABLE 410 VEEVA SYSTEMS: PRODUCTS OFFERED 457
TABLE 411 VEEVA SYSTEMS: PRODUCT LAUNCHES AND APPROVALS,
JANUARY 2022–OCTOBER 2025 458
TABLE 412 VEEVA SYSTEMS: DEALS, JANUARY 2022–OCTOBER 2025 460
TABLE 413 ICON PLC: COMPANY OVERVIEW 463
TABLE 414 ICON PLC: PRODUCTS OFFERED 464
TABLE 415 ICON PLC: PRODUCT LAUNCHES AND APPROVALS,
JANUARY 2022–OCTOBER 2025 465
TABLE 416 ICON PLC: DEALS, JANUARY 2022–OCTOBER 2025 466
TABLE 417 ECLINICALWORKS: COMPANY OVERVIEW 467
TABLE 418 ECLINICALWORKS: PRODUCTS OFFERED 468
TABLE 419 ECLINICALWORKS: PRODUCT LAUNCHES AND APPROVALS,
JANUARY 2022–OCTOBER 2025 469
TABLE 420 ECLINICALWORKS: DEALS, JANUARY 2022–OCTOBER 2025 470
TABLE 421 ACCENTURE: COMPANY OVERVIEW 471
TABLE 422 ACCENTURE: PRODUCTS OFFERED 473
TABLE 423 ACCENTURE: DEALS, JANUARY 2022–OCTOBER 2025 474
TABLE 424 CVS HEALTH: COMPANY OVERVIEW 475
TABLE 425 CVS HEALTH: PRODUCTS OFFERED 476
TABLE 426 CVS HEALTH: PRODUCT LAUNCHES AND APPROVALS,
JANUARY 2022–OCTOBER 2025 477
TABLE 427 CVS HEALTH: DEALS, JANUARY 2022–OCTOBER 2025 478
TABLE 428 SAS INSTITUTE INC.: COMPANY OVERVIEW 479
TABLE 429 SAS INSTITUTE INC.: PRODUCTS OFFERED 480
TABLE 430 SAS INSTITUTE INC.: PRODUCT LAUNCHES AND APPROVALS,
JANUARY 2022–OCTOBER 2025 481
TABLE 431 SAS INSTITUTE INC.: DEALS, JANUARY 2022–OCTOBER 2025 482
TABLE 432 APRIQOT: COMPANY OVERVIEW 483
TABLE 433 OLER HEALTH: COMPANY OVERVIEW 484
TABLE 434 PERCIPIO HEALTH: COMPANY OVERVIEW 485
TABLE 435 FERRUM HEALTH: COMPANY OVERVIEW 485
TABLE 436 AMPLIFY HEALTH: COMPANY OVERVIEW 486
LIST OF FIGURES
FIGURE 1 CLINICAL ANALYTICS MARKET SEGMENTATION AND REGIONAL SCOPE 37
FIGURE 2 RESEARCH DESIGN 41
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE,
DESIGNATION, AND REGION 45
FIGURE 4 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 47
FIGURE 5 BOTTOM-UP APPROACH 48
FIGURE 6 TOP-DOWN APPROACH 49
FIGURE 7 CAGR PROJECTIONS FROM ANALYSIS OF MARKET DRIVERS 50
FIGURE 8 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 51
FIGURE 9 DATA TRIANGULATION METHODOLOGY 52
FIGURE 10 CLINICAL ANALYTICS MARKET, BY OFFERING, 2025 VS. 2030 (USD MILLION) 54
FIGURE 11 CLINICAL ANALYTICS MARKET, BY DATA SOURCE, 2025 VS. 2030 (USD MILLION) 55
FIGURE 12 CLINICAL ANALYTICS MARKET, BY USE CASE, 2025 VS. 2030 (USD MILLION) 56
FIGURE 13 CLINICAL ANALYTICS MARKET, BY END USER, 2025 VS. 2030 (USD MILLION) 57
FIGURE 14 CLINICAL ANALYTICS MARKET: GEOGRAPHICAL SNAPSHOT 58
FIGURE 15 EXPANDING HEALTHCARE INFRASTRUCTURE AND GROWING
ADOPTION OF AI TO DRIVE MARKET 59
FIGURE 16 HEALTHCARE USE CASES AND US LED NORTH AMERICAN MARKET IN 2024 60
FIGURE 17 INDIA TO HAVE HIGHEST GROWTH RATE DURING FORECAST PERIOD 61
FIGURE 18 EMERGING MARKETS TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD 62
FIGURE 19 CLINICAL ANALYTICS MARKET: DRIVERS, RESTRAINTS,
OPPORTUNITIES, AND CHALLENGES 64
FIGURE 20 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 74
FIGURE 21 CLINICAL ANALYTICS MARKET: SUPPLY CHAIN ANALYSIS 81
FIGURE 22 CLINICAL ANALYTICS MARKET: ECOSYSTEM ANALYSIS 83
FIGURE 23 CLINICAL ANALYTICS MARKET: INVESTMENT AND FUNDING SCENARIO 84
FIGURE 24 JURISDICTION AND TOP APPLICANT ANALYSIS CLINICAL ANALYTICS SOLUTIONS 89
FIGURE 25 CLINICAL ANALYTICS MARKET: PATENT ANALYSIS,
JANUARY 2015–SEPTEMBER 2025 91
FIGURE 26 CLINICAL ANALYTICS MARKET: PORTER’S FIVE FORCES ANALYSIS 104
FIGURE 27 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS 107
FIGURE 28 KEY BUYING CRITERIA, BY END USER 108
FIGURE 29 MARKET POTENTIAL OF CLINICAL ANALYTICS ACROSS INDUSTRIES 114
FIGURE 30 PRICE IMPACT ANALYSIS 125
FIGURE 31 NORTH AMERICA: CLINICAL ANALYTICS MARKET SNAPSHOT 188
FIGURE 32 ASIA PACIFIC: CLINICAL ANALYTICS MARKET SNAPSHOT 237
FIGURE 33 REVENUE ANALYSIS OF KEY PLAYERS IN CLINICAL ANALYTICS MARKET,
2020–2024 323
FIGURE 34 MARKET SHARE ANALYSIS OF KEY PLAYERS IN CLINICAL
ANALYTICS MARKET, 2024 324
FIGURE 35 CLINICAL ANALYTICS MARKET: KEY PLAYERS, 2024 327
FIGURE 36 EV/EBITDA OF KEY VENDORS 327
FIGURE 37 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK
BETA OF KEY VENDORS 328
FIGURE 38 CLINICAL ANALYTICS MARKET: BRAND/PRODUCT COMPARISON 329
FIGURE 39 CLINICAL ANALYTICS MARKET: COMPANY EVALUATION MATRIX
(KEY PLAYERS), 2024 331
FIGURE 40 CLINICAL ANALYTICS MARKET: COMPANY EVALUATION MATRIX
(STARTUPS/SMES), 2024 339
FIGURE 41 IQVIA: COMPANY SNAPSHOT (2024) 345
FIGURE 42 OPTUM, INC.: COMPANY SNAPSHOT (2024) 353
FIGURE 43 GE HEALTHCARE: COMPANY SNAPSHOT (2024) 369
FIGURE 44 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2024) 376
FIGURE 45 ORACLE: COMPANY SNAPSHOT (2024) 384
FIGURE 46 MCKESSON CORPORATION: COMPANY SNAPSHOT (2024) 391
FIGURE 47 VERADIGM LLC: COMPANY SNAPSHOT (2022) 397
FIGURE 48 WNS (HOLDINGS) LTD.: COMPANY SNAPSHOT (2024) 408
FIGURE 49 SOPHIA GENETICS: COMPANY SNAPSHOT (2024) 413
FIGURE 50 HEALTH CATALYST: COMPANY SNAPSHOT (2024) 421
FIGURE 51 COGNIZANT: COMPANY SNAPSHOT (2024) 426
FIGURE 52 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2024) 431
FIGURE 53 KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT (2024) 437
FIGURE 54 DASSAULT SYSTÈMES: COMPANY SNAPSHOT (2024) 442
FIGURE 55 VEEVA SYSTEMS: COMPANY SNAPSHOT (2024) 456
FIGURE 56 ICON PLC: COMPANY SNAPSHOT (2024) 464
FIGURE 57 ACCENTURE: COMPANY SNAPSHOT (2024) 472
FIGURE 58 CVS HEALTH: COMPANY SNAPSHOT (2024) 476
MarketsandMarkets（マーケッツアンドマーケッツ）は世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。広範な市場を対象にした市場調査レポートを出版しています。
※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間～12時間以内（営業日基準）にご納品可能です。
ライセンス別価格表
調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。
ライセンスタイプ1
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD4,950 | USD6,650 | USD8,150 | USD10,000 |
ライセンスタイプ2
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD7,150 | USD8,500 | USD9,650 | USD11,000 |
ライセンスタイプ3
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD8,150 | お問合せください | お問合せください | お問合せください |
ライセンスタイプ4
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD9,000 | USD10,500 | USD12,000 | USD13,500 |
ミニレポート ※定性調査にフォーカスした調査レポートです。詳細はお問合せください。
| シングルユーザ | コーポレート |
| USD 2,650 | USD 4,250 |
ご購入に関するご案内
価格・納期について
- 価格
- ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
- ライセンス
- シングルユーザライセンス
- 1名のみレポートファイルのご利用が可能です。
- マルチユーザライセンス
- 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
- コーポレートライセンス
- 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
- エンタープライズサイトライセンス
- 特別ライセンスです。適用範囲についてはお問合せください。
- シングルユーザライセンス
- 納品形態
- Eメール
- 納期
- 最短3時間以内にご納品可能です。通常ご注文後24時間以内（営業日基準）
ご注文方法
- レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。
その他
- 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。
株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。
最新調査レポート
- 自動車用アラミド繊維市場規模、シェア、動向、2030年までの世界予測 2025-12-15
- ポリヒドロキシアルカノエート (PHA) 市場規模、シェア、動向、2030年までの世界予測 2025-12-15
- 複合輸送市場規模、シェア、動向、2032年までの世界予測 2025-12-12
- 有機酸市場規模、シェア、動向、2030年までの世界予測 2025-12-11
- ハイブリッドボンディング市場規模、シェア、動向、2032年までの世界予測 2025-12-11